```
=> b reg
FILE 'REGISTRY' ENTERED AT 17:25:19 ON 20 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 NOV 2008  HIGHEST RN 1073427-79-8
DICTIONARY FILE UPDATES:  19 NOV 2008  HIGHEST RN 1073427-79-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l10
L6              STR
```




```
REP G1=(0-4) 12
NODE ATTRIBUTES:
NSPEC   IS RC     AT  12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E4 C  E2 N  AT   8
ECOUNT  IS M1 N  AT  11

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  12

STEREO ATTRIBUTES: NONE
L8         4374 SEA FILE=REGISTRY ABB=ON  PLU=ON  NC6/ES AND NCNC3/ES
L10        1586 SEA FILE=REGISTRY SUB=L8 SSS FUL L6

100.0% PROCESSED    4180 ITERATIONS                          1586 ANSWERS
SEARCH TIME: 00.00.01


=> b hcap
FILE 'HCAPLUS' ENTERED AT 17:25:28 ON 20 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
```

strictly prohibited.

FILE COVERS 1907 - 20 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 19 Nov 2008 (20081119/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitstr l15 1

L15 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:383484 HCAPLUS
DN 144:428460
TI Method for measuring cell migration activity
IN Shibayama, Shiro; Takeda, Kazuhiko; Watanabe, Noriki; Sugiyama, Tetsuya
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2006043586	A1	20060427	2005WO-JP0019187	20051019

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI 2004JP-000305003 A 20041020

AB A method is provided for measuring the cell migration activity corresponding to the function of a specific cell migration inducer in vivo. The method comprises: (1) a process for transferring cells producing a cell migration inducer (e.g., MDC, SDF-1) into an air-pouch produced under a skin of a mammal (e.g., mouse) ; (2) a process for transferring cells to be measured (e.g., T cells, B cells, monocytes, macrophages, granulocytes) into a site other than the air-pouch of the mammal; (3) a process for recovering the cells in the air-pouch; and (4) a process for measuring the number of the cells to be measured in the recovered cells. Also provided are a method for evaluating a cell migration inhibitory compound possessing a specificity or a selectivity in vivo using the above method; and a method for producing the above cell migration inhibitory compound

IT 710981-61-6
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(method for measuring cell migration activity)

RN 710981-61-6 HCAPLUS
CN Methanone, cyclohexyl[(3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino][1,4'-bipiperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitrn fhitstr l15 2

L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:515487 HCAPLUS

DN 141:71555

TI Preparation of nitrogen-containing heterocyclic compounds as CXCR4 regulators

IN Habashita, Hiromu; Kokubo, Masaya; Shibayama, Shiro; Tada, Hideaki; Tanihiro, Tatsuya

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 641 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2004052862	A1	20040624	2003WO-JP0015718	20031209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2003288994	A1	20040630	2003AU-0002288994	20031209
EP-----1571146	A1	20050907	2003EP-0007787S3	20031209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US-20070167459	A1	20070719	2005US-0005387S8	20050610
PRAI 2002JP-0003S7446	A	20021210		
2003JP-0001627O6	A	20030606		
2003WO-JP0015718	W	20031209		

OS MARPAT 141:71555

GI



AB Compds. such as pyrimidine and quinazoline derivs. represented by the following general formulas (I) and (II), salts thereof, N-oxides thereof, solvates thereof or prodrugs of the same (wherein the ring A represents an optionally substituted nitrogen-containing heterocycle; the ring B represents an optionally substituted homocycle or an optionally substituted heterocycle; Y represents an optionally substituted hydrocarbyl group, an optionally substituted heterocyclic group, an optionally protected amino group, an optionally protected hydroxyl group or an optionally protected mercapto group; and T represents the ring A or an optionally substituted amino group) are prepared. These compds. are CXCR4 regulators, in particular CXCR4 antagonists, and useful as preventives and/or remedies for various inflammatory diseases, immune diseases, various allergic diseases, infectious diseases, acquired immunodeficiency syndrome, infection with human immunodeficiency virus, psychiatric disorder, neurol. disease, cerebral diseases, cardiovascular diseases, metabolic diseases, or cancer, and agents for regeneration therapy, in particular transplant therapy. An assay system using SDF-1 which is an endogenous ligand of CXCR4 receptor, instead of HIV, was used in an assay for screening compds. which inhibit the binding of HIV to CXCR4 or CCR4 receptors on CD4-pos. cells. All the compds. prepared showed IC50 of 10 μM for inhibiting the binding of [125I]human SDF-1 to CEM cells, more specifically 0.1 μM for 2-(1-benzylpyrrolidin-3-ylamino)-4-(perhydroazepin-1-yl)pyrimidine. An ampule and tablet formulation containing 2-[[2-(dimethylamino)ethyl]amino]-4-(perhydroazepin-1-yl)pyrimidine were described.

IT 710978-26-0P 710978-30-6P 710978-41-9P
710978-49-7P 710978-55-5P 710978-59-9P

L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

710978-64-6P 710978-70-4P 710979-06-9P
710979-13-8P 710979-47-8P 710979-52-5P
710979-57-0P 710979-61-6P 710979-68-3P
710979-72-9P 710979-75-2P 710979-80-9P
710979-86-5P 710979-90-1P 710979-97-8P
710980-03-3P 710980-09-9P 710980-15-7P
710980-23-7P 710980-40-8P 710980-47-5P
710980-52-2P 710980-59-9P 710980-78-2P
710980-84-0P 710980-99-7P 710981-09-2P
710981-15-0P 710981-21-8P 710981-39-8P
710981-47-8P 710981-54-7P 710981-61-6P
710981-68-3P 710981-76-3P 710981-83-2P
710981-90-1P 710981-97-8P 710982-16-4P
710982-22-2P 710982-39-1P 710982-81-3P
710982-85-7P 710982-89-1P 710982-93-7P
710982-99-3P 710983-04-3P 710983-09-8P
710983-14-5P 710983-18-9P 710983-22-5P
710983-27-0P 710983-31-6P 710983-35-0P
710983-40-7P 710983-46-3P 710983-55-4P
710983-74-7P 710983-78-1P 710983-82-7P
710983-86-1P 710983-90-7P 710984-39-7P
710984-43-3P 710984-47-7P 710984-51-3P
710984-55-7P 710984-72-8P 710985-84-5P
710985-86-7P 710985-88-9P 710985-90-3P
710985-92-5P 710985-94-7P 710985-96-9P
710985-98-1P 710986-00-8P 710986-02-0P
710986-05-3P 710986-08-6P 710986-11-1P
710986-14-4P 710986-17-7P 710986-20-2P
710986-23-5P 710986-26-8P 710986-29-1P
710986-33-7P 710986-36-0P 710986-39-3P
710986-42-8P 710986-45-1P 710986-49-5P
710986-53-1P 710986-56-4P 710986-59-7P
710986-62-2P 710986-65-5P 710986-68-8P
710986-71-3P 710986-74-6P 710986-77-9P
710986-81-5P 710986-85-9P 710986-89-3P
710986-93-9P 710986-96-2P 710987-00-1P
710987-04-5P 710987-08-9P 710987-12-5P
710987-15-8P 710987-18-1P 710987-23-6P
710987-24-9P 710987-27-2P 710987-30-7P
710987-34-1P 710987-37-4P 710987-40-9P
710987-43-2P 710987-46-5P 710987-48-7P
710987-51-2P 710987-54-5P 710987-57-8P
710987-60-3P 710987-63-6P 710987-66-9P
710987-69-2P 710987-72-7P 710987-76-1P
710987-79-4P 710987-82-9P 710987-85-2P
710987-88-5P 710987-90-9P 710987-94-3P
710987-97-6P 710988-00-4P 710988-04-8P
710988-07-1P 710988-10-6P 710988-13-9P
710988-16-2P 710988-19-5P 710988-22-0P
710988-25-3P 710988-28-6P 710988-31-1P
710988-35-5P 710988-38-8P 710988-41-3P
710988-44-6P 710988-47-9P 710988-50-4P
710988-53-7P 710988-56-0P 710988-59-3P
710988-62-8P 710988-65-1P 710988-68-4P
710988-71-9P 710988-74-2P 710988-77-5P
710988-80-0P 710988-83-3P 710988-87-7P
710988-90-2P 710988-94-6P 710988-97-9P
710989-00-7P 710989-03-0P 710989-06-3P
710989-09-6P 710989-12-1P 710989-15-4P
710989-18-7P 710989-21-2P 710989-24-5P
710989-27-8P 710989-31-4P 710989-34-7P
710989-37-0P 710989-40-5P 710989-43-8P
710989-45-0P 710989-48-3P 710989-50-7P
710989-53-0P 710989-56-3P 710989-59-6P
710989-62-1P 710989-65-4P 710989-68-7P
710989-71-2P 710989-74-5P 710989-77-8P
710989-80-3P 710989-85-8P 710989-88-1P
710989-90-5P 710989-93-8P 710989-96-1P
710989-99-4P 710990-01-5P 710990-03-7P
710990-06-0P 710990-08-2P 710990-10-6P

L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

710990-13-9P 710990-16-2P 710990-19-5P
710990-22-0P 710990-25-3P 710990-28-6P
710990-31-1P 710990-34-4P 710990-37-7P
710990-40-2P 710990-43-5P 710990-45-7P
710990-48-0P 710990-52-6P 710990-54-8P
710990-56-0P 710990-59-3P 710990-62-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)

IT 710990-65-1P 710990-68-4P 710990-71-9P
710990-74-2P 710990-77-5P 710990-80-0P
710990-82-2P 710990-83-3P 710990-84-4P
710990-86-6P 710990-88-8P 710990-90-2P
710990-92-4P 710990-94-6P 710990-96-8P
710990-98-0P 710991-00-7P 710991-02-9P
710991-03-0P 710991-05-2P 710991-07-4P
710991-09-6P 710991-11-0P 710991-13-2P
710991-15-4P 710991-18-7P 710991-20-1P
710991-23-4P 710991-25-6P 710991-27-8P
710991-29-0P 710991-31-4P 710991-33-6P
710991-35-8P 710991-37-0P 710991-39-2P
710991-41-6P 710991-44-9P 710991-46-1P
710991-48-3P 710991-50-7P 710991-52-9P
710991-54-1P 710991-56-3P 710991-59-6P
710991-62-1P 710991-64-3P 710991-66-5P
710991-68-7P 710991-70-1P 710991-72-3P
710991-74-5P 710991-76-7P 710991-78-9P
710991-81-4P 710991-84-7P 710991-87-0P
710991-88-1P 710991-90-5P 710991-92-7P
710991-94-9P 710991-95-0P 710991-97-2P
710991-99-4P 710992-01-1P 710992-02-2P
710992-03-3P 710992-04-4P 710992-05-5P
710992-06-6P 710992-07-7P 710992-08-8P
710992-09-9P 710992-10-2P 710992-11-3P
710992-12-4P 710992-13-5P 710992-14-6P
710992-15-7P 710992-16-8P 710992-17-9P
710992-18-0P 710992-19-1P 710992-20-4P
710992-21-5P 710992-22-6P 710992-23-7P
710992-24-8P 710992-25-9P 710992-26-0P
710992-27-1P 710992-28-2P 710992-29-3P
710992-30-6P 710992-31-7P 710992-32-8P
710992-33-9P 710992-34-0P 710992-35-1P
710992-36-2P 710992-37-3P 710992-38-4P
710992-39-5P 710992-40-8P 710992-41-9P
710992-42-0P 710992-43-1P 710992-44-2P
710992-45-3P 710992-46-4P 710992-47-5P
710992-48-6P 710992-49-7P 710992-50-0P
710992-51-1P 710992-52-2P 710992-53-3P
710992-54-4P 710992-55-5P 710992-56-6P
710992-57-7P 710992-59-9P 710992-60-2P
710992-61-3P 710992-62-4P 710992-63-5P
710992-64-6P 710992-65-7P 710992-66-8P
710992-67-9P 710992-68-0P 710992-69-1P
710992-70-4P 710992-71-5P 710992-72-6P
710992-73-7P 710992-74-8P 710992-75-9P
710992-76-0P 710992-77-1P 710992-78-2P
710992-79-3P 710992-80-6P 710992-81-7P
710992-82-8P 710992-83-9P 710992-85-1P
710992-86-2P 710992-87-3P 710992-88-4P
710992-89-5P 710992-90-8P 710992-91-9P
710992-92-0P 710992-93-1P 710992-94-2P
710992-95-3P 710992-96-4P 710992-97-5P
710992-98-6P 710992-99-7P 710993-00-3P
710993-01-4P 710993-02-5P 710993-03-6P
710993-04-7P 710993-05-8P 710993-06-9P
710993-07-0P 710993-08-1P 710993-09-2P
710993-11-6P 710993-12-7P 710993-13-8P
710993-14-9P 710993-15-0P 710993-16-1P
710993-17-2P 710993-18-3P 710993-19-4P
710993-20-7P 710993-21-8P 710993-22-9P
710993-23-0P 710993-24-1P 710993-25-2P
710993-26-3P 710993-27-4P 710993-28-5P

L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

710993-29-6P 710993-30-9P 710993-31-0P
710993-32-1P 710993-33-2P 710993-34-3P
710993-35-4P 710993-36-5P 710993-37-6P
710993-38-7P 710993-39-8P 710993-40-1P
710993-41-2P 710993-42-3P 710993-43-4P
710993-44-5P 710993-45-6P 710993-46-7P
710993-47-8P 710993-49-0P 710993-50-3P
710993-52-5P 710993-54-7P 710993-56-9P
710993-58-1P 710993-60-5P 710993-62-7P
710993-64-9P 710993-66-1P 710993-68-3P
710993-69-4P 710993-71-8P 710993-73-0P
710993-75-2P 710993-77-4P 710993-78-5P
710993-80-9P 710993-81-0P 710993-83-2P
710993-85-4P 710993-87-6P 710993-89-8P
710993-91-2P 710993-93-4P 710993-94-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)

IT 710993-95-6P 710993-96-7P 710993-97-8P
710993-98-9P 710993-99-0P 710994-00-6P
710994-01-7P 710994-02-8P 710994-03-9P
710994-04-0P 710994-05-1P 710994-06-2P
710994-07-3P 710994-08-4P 710994-09-5P
710994-10-8P 710994-11-9P 710994-12-0P
710994-13-1P 710994-14-2P 710994-15-3P
710994-16-4P 710994-17-5P 710994-18-6P
710994-19-7P 710994-20-0P 710994-21-1P
710994-22-2P 710994-23-3P 710994-24-4P
710994-25-5P 710994-26-6P 710994-28-8P
710994-29-9P 710994-30-2P 710994-31-3P
710994-32-4P 710994-33-5P 710994-35-7P
710994-37-9P 710994-39-1P 710994-41-5P
710994-43-7P 710994-45-9P 710994-47-1P
710994-50-6P 710994-51-7P 710994-52-8P
710994-54-0P 710994-55-1P 710994-56-2P
710994-57-3P 710994-59-5P 710994-60-8P
710994-61-9P 710994-62-0P 710994-63-1P
710994-64-2P 710994-65-3P 710994-66-4P
710994-67-5P 710994-68-6P 710994-69-7P
710994-70-0P 710994-71-1P 710994-72-2P
710994-73-3P 710994-74-4P 710994-75-5P
710994-76-6P 710994-77-7P 710994-78-8P
710994-79-9P 710994-80-2P 710994-84-6P
710994-87-9P 710994-88-0P 710994-89-1P
710994-91-5P 710994-92-6P 710994-93-7P
710994-94-8P 710994-96-0P 710994-97-1P
710994-98-2P 710994-99-3P 710995-00-9P
710995-01-0P 710995-02-1P 710995-03-2P
710995-05-4P 710995-06-5P 710995-07-6P
710995-08-7P 710995-09-8P 710995-10-1P
710995-11-2P 710995-12-3P 710995-13-4P
710995-14-5P 710995-15-6P 710995-16-7P
710995-18-9P 710995-19-0P 710995-20-3P
710995-21-4P 710995-22-5P 710995-24-7P
710995-25-8P 710995-27-0P 710995-28-1P
710995-30-5P 710995-32-7P 710995-33-8P
710995-34-9P 710995-36-1P 710995-37-2P
710995-39-4P 710995-40-7P 710995-41-8P
710995-42-9P 710995-43-0P 710995-45-2P
710995-48-5P 710995-49-6P 710995-51-0P
710995-52-1P 710995-53-2P 710995-54-3P
710995-55-4P 710995-56-5P 710995-58-7P
710995-59-8P 710995-60-1P 710995-61-2P
710995-62-3P 710995-64-5P 710995-65-6P
710995-66-7P 710995-67-8P 710995-68-9P
710995-69-0P 710995-70-3P 710995-71-4P
710995-72-5P 710995-73-6P 710995-74-7P
710995-76-9P 710995-78-1P 710995-80-5P
710995-82-7P 710995-83-8P 710995-84-9P
710995-85-0P 710995-86-1P 710995-87-2P
710995-88-3P 710995-89-4P 710995-90-7P
710995-91-8P 710995-92-9P 710995-93-0P

L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
710995-94-1P 710995-95-2P 710995-96-3P
710995-97-4P 710995-98-5P 710995-99-6P
710996-00-2P 710996-01-3P 710996-02-4P
710996-03-5P 710996-04-6P 710996-05-7P
710996-06-8P 710996-07-9P 710996-08-0P
710996-09-1P 710996-10-4P 710996-11-5P
710996-12-6P 710996-13-7P 710996-14-8P
710996-15-9P 710996-16-0P 710996-17-1P
710996-18-2P 710996-19-3P 710996-20-6P
710996-21-7P 710996-22-8P 710996-23-9P
710996-24-0P 710996-25-1P 710996-26-2P
710996-27-3P 710996-28-4P 710996-29-5P
710996-30-8P 710996-31-9P 710996-32-0P
710996-33-1P 710996-34-2P 710996-35-3P
710996-36-4P 710996-37-5P 710996-38-6P
710996-39-7P 710996-40-0P 710996-41-1P
710996-42-2P 710996-43-3P 710996-44-4P
710996-45-5P 710996-46-6P 710996-47-7P
710996-48-8P 710996-49-9P 710996-50-2P
710996-51-3P 710996-52-4P 710996-53-5P
710996-54-6P 710996-55-7P 710996-56-8P
710996-57-9P 710996-58-0P 710996-59-1P
710996-60-4P 710996-61-5P 710996-62-6P
710996-63-7P 710996-64-8P 710996-65-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)
IT 710996-66-0P 710996-67-1P 710996-68-2P
710996-69-3P 710996-70-6P 710996-71-7P
710996-72-8P 710996-73-9P 710996-74-0P
710996-75-1P 710996-76-2P 710996-77-3P
710996-78-4P 710996-79-5P 710996-80-8P
710996-81-9P 710996-82-0P 710996-83-1P
710996-84-2P 710996-85-3P 710996-86-4P
710996-87-5P 710996-88-6P 710996-89-7P
710996-90-0P 710996-91-1P 710996-92-2P
710996-93-3P 710996-94-4P 710996-95-5P
710996-96-6P 710996-97-7P 710996-98-8P
710996-99-9P 710997-00-5P 710997-01-6P
710997-02-7P 710997-03-8P 710997-04-9P
710997-05-0P 710997-06-1P 710997-07-2P
710997-08-3P 710997-09-4P 710997-10-7P
710997-11-8P 710997-12-9P 710997-13-0P
710997-14-1P 710997-15-2P 710997-16-3P
710997-17-4P 710997-18-5P 710997-19-6P
710997-20-9P 710997-21-0P 710997-22-1P
710997-23-2P 710997-24-3P 710997-25-4P
710997-26-5P 710997-27-6P 710997-28-7P
710997-29-8P 710997-30-1P 710997-31-2P
710997-32-3P 710997-33-4P 710997-34-5P
710997-35-6P 710997-36-7P 710997-37-8P
710997-38-9P 710997-39-0P 710997-40-3P
710997-41-4P 710997-42-5P 710997-43-6P
710997-44-7P 710997-45-8P 710997-46-9P
710997-47-0P 710997-48-1P 710997-49-2P
710997-50-5P 710997-51-6P 710997-52-7P
710997-53-8P 710997-54-9P 710997-55-0P
710997-56-1P 710997-57-2P 710997-58-3P
710997-59-4P 710997-60-7P 710997-61-8P
710997-62-9P 710997-63-0P 710997-64-1P
710997-65-2P 710997-66-3P 710997-67-4P
710997-68-5P 710997-69-6P 710997-70-9P
710997-71-0P 710997-72-1P 710997-73-2P
710997-74-3P 710997-75-4P 710997-76-5P
710997-77-6P 710997-78-7P 710997-79-8P
710997-80-1P 710997-81-2P 710997-82-3P
710997-83-4P 710997-84-5P 710997-85-6P
710997-86-7P 710997-87-8P 710997-88-9P

L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
710997-89-0P 710997-90-3P 710997-91-4P
710997-92-5P 710997-93-6P 710997-94-7P
710997-95-8P 710997-96-9P 710997-97-0P
710997-98-1P 710997-99-2P 710998-00-8P
710998-01-9P 710998-02-0P 710998-03-1P
710998-04-2P 710998-05-3P 710998-06-4P
710998-07-5P 710998-08-6P 710998-09-7P
710998-10-0P 710998-11-1P 710998-12-2P
710998-13-3P 710998-14-4P 710998-15-5P
710998-16-6P 710998-17-7P 710998-18-8P
710998-19-9P 710998-20-2P 710998-21-3P
710998-22-4P 710998-23-5P 710998-24-6P
710998-25-7P 710998-26-8P 710998-27-9P
710998-28-0P 710998-29-1P 710998-30-4P
710998-31-5P 710998-32-6P 710998-33-7P
710998-34-8P 710998-35-9P 710998-36-0P
710998-37-1P 710998-38-2P 710998-39-3P
710998-40-6P 710998-41-7P 710998-42-8P
710998-43-9P 710998-44-0P 710998-45-1P
710998-46-2P 710998-47-3P 710998-48-4P
710998-49-5P 710998-50-8P 710998-51-9P
710998-52-0P 710998-53-1P 710998-54-2P
710998-55-3P 710998-56-4P 710998-57-5P
710998-58-6P 710998-59-7P 710998-60-0P
710998-61-1P 710998-62-2P 710998-63-3P
711000-15-6P 711000-16-7P 711000-17-8P
711000-18-9P 711001-40-0P 711001-75-1P
711001-76-2P 711002-69-6P 711002-70-9P
711002-71-0P 711002-72-1P 711002-75-4P
711002-76-5P 711002-77-6P 711002-78-7P
711002-79-8P 711002-80-1P 711002-81-2P
711002-82-3P 711002-83-4P 711002-84-5P
711002-85-6P 711002-86-7P 711002-87-8P
711002-88-9P 711002-89-0P 711002-90-3P
711002-91-4P 711002-92-5P 711002-93-6P
711002-94-7P 711002-95-8P 711002-96-9P
711002-97-0P 711002-98-1P 711002-99-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)
IT 711003-00-8P 711003-01-9P 711003-02-0P
711003-03-1P 711003-04-2P 711003-05-3P
711003-06-4P 711003-07-5P 711003-08-6P
711003-09-7P 711003-11-1P 711003-12-2P
711003-13-3P 711003-14-4P 711003-15-5P
711003-16-6P 711003-17-7P 711003-18-8P
711003-19-9P 711003-20-2P 711003-21-3P
711003-22-4P 711003-23-5P 711003-24-6P
711003-25-7P 711003-26-8P 711003-27-9P
711003-28-0P 711003-29-1P 711003-30-4P
711003-31-5P 711003-32-6P 711003-33-7P
711003-34-8P 711003-35-9P 711003-36-0P
711003-37-1P 711003-38-2P 711003-39-3P
711003-40-6P 711003-41-7P 711003-42-8P
711003-43-9P 711003-44-0P 711003-45-1P
711003-46-2P 711003-47-3P 711003-48-4P
711003-49-5P 711003-50-8P 711003-51-9P
711003-52-0P 711003-53-1P 711003-54-2P
711003-84-8P 711003-96-2P 711003-99-5P
711004-02-3P 711004-03-4P 711004-04-5P
711004-05-6P 711004-06-7P 711004-07-8P
711004-08-9P 711004-09-0P 711004-10-3P
711004-11-4P 711004-12-5P 711004-13-6P
711004-14-7P 711004-15-8P 711004-16-9P
711004-17-0P 711004-18-1P 711004-19-2P
711004-20-5P 711004-21-6P 711004-22-7P
711004-23-8P 711004-24-9P 711004-25-0P
711004-26-1P 711004-27-2P 711004-28-3P

L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
711004-29-4P 711004-30-7P 711004-31-8P
711004-32-9P 711004-33-0P 711004-34-1P
711004-35-2P 711004-36-3P 711004-37-4P
711004-38-5P 711004-39-6P 711004-40-9P
711004-41-0P 711004-42-1P 711004-43-2P
711004-44-3P 711004-45-4P 711004-46-5P
711004-47-6P 711004-48-7P 711004-49-8P
711004-50-1P 711004-51-2P 711004-52-3P
711004-53-4P 711004-54-5P 711004-55-6P
711004-56-7P 711004-57-8P 711004-58-9P
711004-59-0P 711004-60-3P 711004-61-4P
711004-62-5P 711004-63-6P 711004-76-1P
711004-77-2P 711004-78-3P 711004-79-4P
711004-80-7P 711004-81-8P 711004-82-9P
711004-83-0P 711004-84-1P 711004-85-2P
711004-86-3P 711004-87-4P 711004-88-5P
711004-89-6P 711004-90-9P 711004-91-0P
711004-92-1P 711004-93-2P 711004-94-3P
711004-95-4P 711004-96-5P 711004-97-6P
711004-99-8P 711005-00-4P 711005-01-5P
711005-02-6P 711005-03-7P 711005-04-8P
711005-05-9P 711005-06-0P 711005-07-1P
711005-08-2P 711005-09-3P 711005-10-6P
711005-11-7P 711005-12-8P 711005-13-9P
711005-14-0P 711005-15-1P 711005-16-2P
711005-17-3P 711005-18-4P 711005-19-5P
711005-20-8P 711005-21-9P 711005-22-0P
711005-23-1P 711005-24-2P 711005-25-3P
711005-26-4P 711005-27-5P 711005-28-6P
711005-29-7P 711005-30-0P 711005-31-1P
711005-32-2P 711005-33-3P 711005-34-4P
711005-35-5P 711005-36-6P 711005-37-7P
711005-38-8P 711005-39-9P 711005-40-2P
711005-41-3P 711005-42-4P 711005-43-5P
711005-44-6P 711005-45-7P 711005-46-8P
711005-47-9P 711005-48-0P 711005-49-1P
711005-50-4P 711005-51-5P 711005-52-6P
711005-53-7P 711005-54-8P 711005-55-9P
711005-56-0P 711005-57-1P 711005-58-2P
711005-59-3P 711005-60-6P 711005-61-7P
711005-62-8P 711005-63-9P 711005-64-0P
711005-65-1P 711005-66-2P 711005-67-3P
711005-68-4P 711005-69-5P 711005-70-8P
711005-71-9P 711005-72-0P 711005-73-1P
711005-74-2P 711005-75-3P 711005-76-4P
711005-77-5P 711005-78-6P 711005-79-7P
711005-80-0P 711005-81-1P 711005-82-2P
711005-83-3P 711005-84-4P 711005-85-5P
711005-86-6P 711005-87-7P 711005-88-8P
711005-89-9P 711005-90-2P 711005-91-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)
IT 711005-92-4P 711005-93-5P 711005-94-6P
711005-95-7P 711005-96-8P 711005-97-9P
711005-98-0P 711005-99-1P 711006-00-7P
711006-01-8P 711006-02-9P 711006-03-0P
711006-04-1P 711006-05-2P 711006-06-3P
711006-07-4P 711006-08-5P 711006-09-6P
711006-10-9P 711006-11-0P 711006-12-1P
711006-13-2P 711006-14-3P 711006-15-4P
711006-16-5P 711006-17-6P 711006-18-7P
711006-19-8P 711006-20-1P 711006-21-2P
711006-22-3P 711006-23-4P 711006-24-5P
711006-25-6P 711006-26-7P 711006-27-8P
711006-28-9P 711006-29-0P 711006-30-3P
711006-31-4P 711006-32-5P 711006-33-6P
711006-34-7P 711006-35-8P 711006-36-9P
711006-37-0P 711006-38-1P 711006-39-2P
711006-40-5P 711006-41-6P 711006-42-7P
711006-43-8P 711006-44-9P 711006-45-0P
711006-46-1P 711006-47-2P 711006-48-3P

L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
711006-49-4P 711006-50-7P 711006-51-8P
711006-52-9P 711006-53-0P 711006-54-1P
711006-55-2P 711006-56-3P 711006-58-5P
711006-59-6P 711006-60-9P 711006-61-0P
711006-62-1P 711006-63-2P 711006-64-3P
711006-65-4P 711006-66-5P 711006-67-6P
711006-68-7P 713138-04-6P 713138-05-7P
713138-06-8P 713138-07-9P 713138-08-0P
713138-09-1P 713138-10-4P 713138-11-5P
713138-12-6P 713138-13-7P 713138-14-8P
713138-15-9P 713138-16-0P 713138-17-1P
713138-18-2P 713138-19-3P 713138-20-6P
713138-21-7P 713138-22-8P 713138-23-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)
IT 711002-21-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nitrogen-containing heterocyclic compds. as CXCR4 antagonists for preparation and/treatment of diseases)
IT 710978-26-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrogen-containing heterocyclic compds. as CXCR4 antagonists for preparation and/treatment of diseases)
RN 710978-26-0 HCAPLUS
CN 2-Pyrimidinamine, N-(3S)-[1,1'-bipiperidin]-3-yl-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr l16 tot

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:968323 HCAPLUS
DN 147:315118
TI CXCR4- and CXCL12/SDF-1-inhibiting substances for treatment of retinal disorders
IN Rodrigues, Gerard A.; Donello, John E.; McLaughlin, Anne P.; Schweighoffer, Fabien J.; Mahe, Florence
PA Can.
SO U.S. Pat. Appl. Publ., 53pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US-20070203089	A1	20070830	2007US-000670883	20070202
AU-2007293169	A1	20080313	2007AU-000293169	20070202
CA-----2640080	A1	20080313	2007CA-002640080	20070202
WO--2008029276	A2	20080313	2007WO-IB0003262	20070202

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI	2006US-00764892P	P	20060202
	2007WO-IB0003262	W	20070202

OS MARPAT 147:315118
GI



I

AB Compns. and methods of treating ocular disorders comprising CXCR4- or CXCL12/SDF-1 inhibitory compns. are disclosed. The compns. may comprise antisense oligonucleotides or RNA interference-mediating dsRNA as well as organic compds. such as I (R = C1-6-alkyl-NH2). Thus, siRNA inhibition of CXCR4 expression in ARPE-19 cells inhibited oxidative stress-induced cell death in a dose-dependent fashion. A 72-yr old patient diagnosed with exudative age-related macular degeneration was given a subconjunctival injection of AMD 3100 in each eye once every 2 wk for 6 mo. At the end of the treatment period the patient displayed an increase in visual acuity.

IT 908021-13-6 908021-14-7 908021-16-9
908021-17-0 908021-22-7 908021-23-8
908021-25-0 908021-37-4 908021-79-4
908021-81-8 908021-83-0 908021-99-8
908022-26-4 908022-30-0 908022-31-1
908022-33-3 908022-34-4 908022-35-5
908022-44-6 908022-45-7 908022-46-8
908022-53-7 908022-64-0 908023-10-9
908023-11-0 908023-12-1 908023-13-2
908023-14-3 908023-15-4 908023-16-5
908023-17-6 908023-18-7 908023-19-8
908023-22-3 908023-23-4 908023-24-5
908023-25-6 908023-26-7 908023-27-8

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908021-17-0 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(5-aminopentyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-22-7 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[2-(dimethylamino)ethyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-23-8 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(dimethylamino)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
908067-77-6 908128-35-8 947392-09-8
947392-11-2 947392-12-3 947392-13-4
947392-14-5 947392-15-6 947392-16-7
947392-17-8 947392-18-9 947392-19-0
947392-20-3 947392-21-4 947392-22-5
947392-23-6 947392-24-7 947392-25-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CXCR4- and CXCL12/SDF-1-inhibiting substances for treatment of retinal disorders)

RN 908021-13-6 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(aminomethyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-14-7 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(2-aminoethyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-16-9 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(3-aminopropyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Absolute stereochemistry.



RN 908021-25-0 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[5-(dimethylamino)pentyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-37-4 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(2-aminoethyl)-1-cyclohexyl-3-piperidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908021-79-4 HCAPLUS
CN 2-Piperidineacetamide, N-(3-aminopropyl)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, (2R,3S)-rel- (CA INDEX NAME)

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Relative stereochemistry.



RN 908021-81-8 HCAPLUS
CN 2-Piperidineacetamide, N-(4-aminobutyl)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, (2R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908021-83-0 HCAPLUS
CN 2-Piperidineacetamide, N-(2-aminoethyl)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, (2R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908021-99-8 HCAPLUS
CN 2-Morpholinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-N-(tetrahydro-2H-pyran-4-yl)-, rel- (CA INDEX NAME)

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-33-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-34-4 HCAPLUS
CN 4-Pyridinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-35-5 HCAPLUS
CN 4-Piperidinecarboxamide, 1-ethyl-N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(1-methylethyl)-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Relative stereochemistry.



RN 908022-26-4 HCAPLUS
CN 2-Piperidineacetamide, 1-cyclohexyl-N-(3-(dimethylamino)propyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, (2R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-30-0 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-1-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-31-1 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-1-ethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-44-6 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1'-(3-fluorobenzoyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino][1,4'-bipiperidin]-2-yl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-45-7 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1'-(cyclohexylcarbonyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino][1,4'-bipiperidin]-2-yl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-46-8 HCAPLUS
CN 2-Morpholinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-53-7 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-hydroxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-64-0 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(3-hydroxypropyl)-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-10-9 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(dipropylamino)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908023-11-0 HCAPLUS
CN Cyclohexanol, 4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-, cis-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-12-1 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(diethylamino)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908023-13-2 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(1-pyrrolidinyl)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-14-3 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(1-piperidinyl)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908023-15-4 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(hexahydro-1H-azepin-1-yl)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-16-5 HCAPLUS
CN Methanone, [4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-1-piperidinyl]cyclohexyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 908023-17-6 HCAPLUS
CN Methanone, [4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-1-piperidinyl]cyclopentyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 908023-18-7 HCAPLUS
CN Methanone, [4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-1-piperidinyl](3-fluorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 908023-19-8 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-22-3 HCAPLUS
CN 2-Morpholinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908023-23-4 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-ethyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-24-5 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(tetrahydro-2H-thiopyran-4-yl)-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-25-6 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(1-methylethyl)-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908023-26-7 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-[2-hydroxy-1-(hydroxymethyl)ethyl]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-27-8 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(tetrahydro-2H-pyran-4-yl)-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908067-77-6 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908128-35-8 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(tetrahydro-1-oxido-2H-thiopyran-4-yl)-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 947392-09-8 HCAPLUS
CN Cyclohexanol, 4-[(2R,3S)-2-[3-(diethylamino)propyl]-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-, cis-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 947392-11-2 HCAPLUS
CN 3-Piperidinecarboxamide, N-[2-[(2S,3R)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, (3S)- (CA INDEX NAME)

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Absolute stereochemistry.



RN 947392-12-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(2-[(2S,3R)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 947392-13-4 HCAPLUS
CN Propanamide, 2-amino-N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-2-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 947392-14-5 HCAPLUS
CN 3-Piperidinecarboxamide, N-[2-[(2S,3R)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 947392-15-6 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-1-(1-methylethyl)-N-(tetrahydro-2H-pyran-4-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 947392-16-7 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-N-(2-methoxyethyl)-1-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 947392-17-8 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-N-(2-hydroxyethyl)-1-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 947392-18-9 HCAPLUS
CN 2-Piperidinecarboxamide, N-[2-[(2S,3R)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 947392-19-0 HCAPLUS
CN Benzenepropanamide, α-amino-N-[2-[(2S,3R)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 947392-20-3 HCAPLUS
CN Butanamide, 2-amino-N-[2-[(2S,3R)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 947392-24-7 HCAPLUS
CN 2-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 947392-25-8 HCAPLUS
CN 2-Pyrimidinamine, N-[2-(3-aminopropyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)



L16 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 947392-21-4 HCAPLUS
CN 4-Piperidinecarboxamide, 1-(2-aminoethyl)-N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 947392-22-5 HCAPLUS
CN 1H-Imidazole-5-propanamide, α-amino-N-[2-[(2S,3R)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 947392-23-6 HCAPLUS
CN 1H-Imidazole-5-propanamide, α-amino-N-[2-[(2S,3R)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, (αS)- (CA INDEX NAME)

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:887712 HCAPLUS
DN 145:293089
TI Preparation of 2-aminopyrimidine compounds as CXCR4 antagonists
IN Ochiai, Hiroshi; Ohhata, Akira; Takaoka, Yoshikazu; Shibayama, Shiro
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 179pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2006090853	A1	20060831	2006WO-JP0303477	20060224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP-----1852432	A1	20071107	2006EP-000714616	20060224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI 2005JP-000050098	A	20050225		
2006WO-JP0303477	W	20060224		

OS MARPAT 145:293089
GI



I



II

AB Title compds. I [ring A = (un)substituted heterocycle containing nitrogen; ring B = optionally substituted unsatd. heterocycle containing nitrogen; ring D = (un)substituted heterocycle containing nitrogen; X = nitrogen, carbon; Y = spacer; R1 = H, (un)substituted hydrocarbon group, (un)substituted cyclic group; R2, R3 = H, (un)substituted hydrocarbon group; (un)substituted cyclic group, etc.; R2 and R3 together with the nitrogen atom to which they bonded may combine to form an optionally substituted heterocycle containing nitrogen.; R4 = H, (un)substituted hydrocarbon group], salts, N-oxide, solvates or prodrugs thereof were prepared For example, reductive amination of 4-(1-azepanyl)-N-[(2R,3S)-2-(azidomethyl)-3-pyrrolidinyl]-2-pyrimidineamine, e.g., prepared from tert-Bu (2R,3S)-3-[(tert-butyldimethylsilyl)oxy]-2-(hydroxymethyl)-1-pyrrolidinecarboxylate in 9 steps, with cyclohexanone followed by Pd/C catalyzed reduction under H2 afforded (2R,3S)-II [R = CH2NH2]. In CXCR4 binding inhibition assays using human stromal cell derived factor 1 (SDF-1), the IC50 value of (2R,3S)-II [R = (CH2)3NH2] was 1.6 nM. Compds. I are claimed useful for the treatment of AIDS, articular rheumatism, etc.
IT 908021-13-6P 908021-14-7P 908021-16-9P 908021-17-0P 908021-18-1P 908021-19-2P

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
908021-20-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 2-aminopyrimidine compds. as CXCR4 antagonists for treatment of AIDS, articular rheumatism, etc.)
RN 908021-13-6 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(aminomethyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-14-7 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(2-aminoethyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-16-9 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(3-aminopropyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 908021-19-2 HCAPLUS
CN 2-Pyrimidinamine, N-[(3S,5S)-5-(2-aminoethyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-20-5 HCAPLUS
CN 2-Pyrimidinamine, N-[(3S,5S)-5-(3-aminopropyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 908021-21-6P 908021-22-7P 908021-23-8P
908021-25-0P 908021-26-1P 908021-27-2P
908021-28-3P 908021-37-4P 908021-38-5P
908021-39-6P 908021-40-9P 908021-41-0P
908021-42-1P 908021-43-2P 908021-44-3P
908021-45-4P 908021-46-5P 908021-47-6P
908021-48-7P 908021-50-1P 908021-51-2P
908021-52-3P 908021-53-4P 908021-54-5P
908021-55-6P 908021-56-7P 908021-57-8P
908021-58-9P 908021-60-3P 908021-61-4P
908021-63-6P 908021-64-7P 908021-65-8P
908021-66-9P 908021-68-1P 908021-70-5P
908021-79-4P 908021-81-8P 908021-83-0P
908021-85-2P 908021-87-4P 908021-88-5P
908021-89-6P 908021-90-9P 908021-94-3P
908021-95-4P 908021-96-5P 908021-97-6P
908021-98-7P 908021-99-8P 908022-00-4P
908022-01-5P 908022-03-7P 908022-06-0P
908022-07-1P 908022-11-7P 908022-12-8P
908022-13-9P 908022-15-1P 908022-19-5P
908022-20-8P 908022-21-9P 908022-25-3P
908022-26-4P 908022-27-5P 908022-28-6P
908022-29-7P 908022-30-0P 908022-31-1P
908022-32-2P 908022-33-3P 908022-34-4P
908022-35-5P 908022-36-6P 908022-37-7P
908022-38-8P 908022-39-9P 908022-40-2P
908022-41-3P 908022-42-4P 908022-44-6P
908022-45-7P 908022-46-8P 908022-47-9P
908022-48-0P 908022-49-1P 908022-50-4P
908022-51-5P 908022-52-6P 908022-53-7P
908022-54-8P 908022-55-9P 908022-56-0P
908022-57-1P 908022-58-2P 908022-59-3P

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908021-17-0 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(5-aminopentyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-18-1 HCAPLUS
CN 2-Pyrimidinamine, N-[(3S,5R)-5-(aminomethyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
908022-60-6P 908022-62-8P 908022-64-0P
908022-65-1P 908022-66-2P 908022-67-3P
908022-68-4P 908022-69-5P 908022-70-8P
908022-71-9P 908022-72-0P 908022-73-1P
908022-74-2P 908022-75-3P 908022-76-4P
908022-77-5P 908022-78-6P 908022-79-7P
908022-80-0P 908022-81-1P 908022-82-2P
908022-83-3P 908022-84-4P 908022-85-5P
908022-86-6P 908022-87-7P 908022-88-8P
908022-89-9P 908022-90-2P 908022-91-3P
908022-92-4P 908022-93-5P 908022-94-6P
908022-95-7P 908022-96-8P 908022-97-9P
908022-98-0P 908022-99-1P 908023-00-7P
908023-01-8P 908023-02-9P 908023-03-0P
908023-04-1P 908023-05-2P 908023-06-3P
908023-07-4P 908023-08-5P 908023-09-6P
908023-10-9P 908023-11-0P 908023-12-1P
908023-13-2P 908023-14-3P 908023-15-4P
908023-16-5P 908023-17-6P 908023-18-7P
908023-19-8P 908023-20-1P 908023-21-2P
908023-22-3P 908023-23-4P 908023-24-5P
908023-25-6P 908023-26-7P 908023-27-8P
908023-35-8P 908023-70-1P 908128-35-8P
908128-36-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-aminopyrimidine compds. as CXCR4 antagonists for treatment of AIDS, articular rheumatism, etc.)
RN 908021-21-6 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[(dimethylamino)methyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-22-7 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[2-(dimethylamino)ethyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-23-8 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(dimethylamino)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 908021-25-0 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[5-(dimethylamino)pentyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-26-1 HCAPLUS
CN 2-Pyrimidinamine, N-[(3S,5R)-1-cyclohexyl-5-[(dimethylamino)methyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908021-38-5 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(2-aminoethyl)-1-(1-methylethyl)-3-piperidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908021-39-6 HCAPLUS
CN Methanone, [(2R,3S)-2-(2-aminoethyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino][1,4'-bipiperidin]-1'-yl](3-fluorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908021-40-9 HCAPLUS
CN Methanone, [(2R,3S)-2-(2-aminoethyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino][1,4'-bipiperidin]-1'-yl]cyclohexyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908021-27-2 HCAPLUS
CN 2-Pyrimidinamine, N-[(3S,5S)-1-cyclohexyl-5-[2-(dimethylamino)ethyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-28-3 HCAPLUS
CN 2-Pyrimidinamine, N-[(3S,5S)-1-cyclohexyl-5-[3-(dimethylamino)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-37-4 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(2-aminoethyl)-1-cyclohexyl-3-piperidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908021-41-0 HCAPLUS
CN Methanone, [4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-1-piperidinyl]cyclohexyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 908021-42-1 HCAPLUS
CN Methanone, [4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-1-piperidinyl]cyclopentyl- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 908021-43-2 HCAPLUS
CN 1-Butanone, 1-[4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-1-piperidinyl]-2-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A

RN 908021-46-5 HCAPLUS
CN Ethanone, 1-[4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-1-piperidinyl]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-47-6 HCAPLUS
CN 2-Pyrimidinamine, N-[(3R,4S)-4-(aminomethyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-48-7 HCAPLUS
CN 2-Pyrimidinamine, N-[(3R,4S)-4-(2-aminoethyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 908021-44-3 HCAPLUS
CN Ethanone, 1-[4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-1-piperidinyl]-2-cyclopentyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-45-4 HCAPLUS
CN Methanone, [4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-1-piperidinyl](3-fluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908021-50-1 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

RN 908021-51-2 HCAPLUS
CN Benzenepropanamide, α-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-(phenylmethoxy)-, trihydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 908021-52-3 HCAPLUS
CN Benzenepropanamide, α-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-(phenylmethoxy)-, trihydrochloride, (αS)- (9CI) (CA INDEX NAME)

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



●3 HCl

RN 908021-53-4 HCAPLUS
CN Butanamide, 2-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-(phenylmethoxy)-, hydrochloride (1:3), (2R)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 908021-54-5 HCAPLUS
CN Butanamide, 2-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-(phenylmethoxy)-, hydrochloride (1:3), (2S)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●3 HCl

RN 908021-57-8 HCAPLUS
CN 3-Morpholinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

RN 908021-58-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(2-[1-cyclohexyl-3-[(4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●3 HCl

RN 908021-55-6 HCAPLUS
CN Propanamide, 2-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-3-(phenylmethoxy)-, hydrochloride (1:3), (2R)- (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 908021-56-7 HCAPLUS
CN Propanamide, 2-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-3-(phenylmethoxy)-, hydrochloride (1:3), (2S)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 908021-60-3 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-ethyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

RN 908021-61-4 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(tetrahydro-2H-thiopyran-4-yl)-2-piperidinyl]ethyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

RN 908021-63-6 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(2-thienylmethyl)-2-piperidinyl]ethyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●3 HCl

RN 908021-64-7 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(1-methylethyl)-2-piperidinyl]ethyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

RN 908021-65-8 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-[2-methyl-2-(phenylmethoxy)propyl]-2-piperidinyl]ethyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●3 HCl

RN 908021-70-5 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(tetrahydro-2H-pyran-4-yl)-2-piperidinyl]ethyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

RN 908021-79-4 HCAPLUS
CN 2-Piperidineacetamide, N-(3-aminopropyl)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, (2R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908021-81-8 HCAPLUS
CN 2-Piperidineacetamide, N-(4-aminobutyl)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, (2R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●3 HCl

RN 908021-66-9 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-[2-hydroxy-1-(hydroxymethyl)ethyl]-2-piperidinyl]ethyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

RN 908021-68-1 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(2-hydroxy-2-methylpropyl)-2-piperidinyl]ethyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908021-83-0 HCAPLUS
CN 2-Piperidineacetamide, N-(2-aminoethyl)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, (2R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908021-85-2 HCAPLUS
CN Methanone, [(2S,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]-1-piperazinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-87-4 HCAPLUS
CN 2-Pyrrolidinecarboxamide, N-(2-aminoethyl)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, (2S,3S)- (CA INDEX NAME)

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Absolute stereochemistry.



RN 908021-88-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, N-(3-aminopropyl)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-89-6 HCAPLUS
CN 2-Pyrrolidinecarboxamide, N-(4-aminobutyl)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908021-90-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, N-(5-aminopentyl)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-94-3 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-N-(2-hydroxyethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908021-95-4 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-N-(tetrahydro-2H-pyran-4-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908021-96-5 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-N-(2-methoxyethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908021-97-6 HCAPLUS
CN 4-Piperidinecarboxamide, N-(2-aminoethyl)-N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908021-98-7 HCAPLUS
CN Glycine, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-N-(4-piperidinylcarbonyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908021-99-8 HCAPLUS
CN 2-Morpholinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-N-(tetrahydro-2H-pyran-4-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-00-4 HCAPLUS
CN Guanidine, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-01-5 HCAPLUS
CN Guanidine, N-[3-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]propyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-03-7 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)-2-piperidinyl]ethyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-11-7 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(1-piperazinyl)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-12-8 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-[3-[bis(1H-imidazol-2-ylmethyl)amino]propyl]-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-13-9 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-(1-piperazinylmethyl)-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-06-0 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[2-[(4-piperidinylmethyl)amino]ethyl]-3-piperidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-07-1 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-[2-[bis(4-piperidinylmethyl)amino]ethyl]-1-cyclohexyl-3-piperidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-15-1 HCAPLUS
CN Ethanesulfonamide, 2-amino-N-[[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-19-5 HCAPLUS
CN Cyclohexanol, 4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-, cis- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-20-8 HCAPLUS
CN Cyclohexanol, 4-[(2R,3S)-2-[3-(diethylamino)propyl]-3-[[4-(hexahydro-1H-

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-, cis- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-21-9 HCAPLUS
CN Cyclohexanol, 4-[(2R,3S)-2-[3-(hexahydro-1H-azepin-1-yl)propyl]-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-, cis- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-25-3 HCAPLUS
CN 2-Pyrimidinamine, N-[(2S,3S)-2-[(2-aminoethoxy)methyl]-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-29-7 HCAPLUS
CN Methanone, [(2S,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-30-0 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-1-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-31-1 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-26-4 HCAPLUS
CN 2-Piperidineacetamide, 1-cyclohexyl-N-(3-(dimethylamino)propyl]-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, (2R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-27-5 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[2-(dimethylamino)ethyl]-3-piperidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-28-6 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[4-(dimethylamino)butyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-1-ethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-32-2 HCAPLUS
CN 2-Pyridinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-33-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-34-4 HCAPLUS
CN 4-Pyridinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-35-5 HCAPLUS
CN 4-Piperidinecarboxamide, 1-ethyl-N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(1-methylethyl)-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-36-6 HCAPLUS
CN Benzamide, 4-amino-N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-37-7 HCAPLUS
CN Pentanamide, N-[2-(1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-methyl-2-(methylamino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-40-2 HCAPLUS
CN 2-Pyridinecarboxamide, 4-(aminomethyl)-N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-41-3 HCAPLUS
CN 1H-Indole-2-carboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-2,3-dihydro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-42-4 HCAPLUS
CN Benzamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-(1-piperazinyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-38-8 HCAPLUS
CN Benzeneacetamide, 4-amino-N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-39-9 HCAPLUS
CN 4-Piperidineacetamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-44-6 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1'-(3-fluorobenzoyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino][1,4'-bipiperidin]-2-yl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-45-7 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1'-(cyclohexylcarbonyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino][1,4'-bipiperidin]-2-yl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-46-8 HCAPLUS
CN 2-Morpholinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-47-9 HCAPLUS
CN 3-Piperidinecarboxamide, N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-48-0 HCAPLUS
CN 3-Piperidinecarboxamide, N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-49-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Absolute stereochemistry.



RN 908022-53-7 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-hydroxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-54-8 HCAPLUS
CN Pentanamide, 5-amino-N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-55-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-hydroxy-, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-50-4 HCAPLUS
CN Propanamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-2,2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-51-5 HCAPLUS
CN 2-Piperidinecarboxamide, N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-52-6 HCAPLUS
CN 2-Piperidinecarboxamide, N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, (2R)- (CA INDEX NAME)

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-56-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-57-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-hydroxy-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-58-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-hydroxy-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-59-3 HCAPLUS
CN 1H-Imidazole-5-propanamide, α-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-60-6 HCAPLUS
CN 1H-Imidazole-5-propanamide, α-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-62-8 HCAPLUS
CN Cyclohexanecarboxamide, 1-amino-N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-67-3 HCAPLUS
CN Butanamide, 2-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-68-4 HCAPLUS
CN Butanamide, 2-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-69-5 HCAPLUS
CN Butanamide, 2-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-3-hydroxy-, (2S,3R)- (CA INDEX

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-64-0 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(3-hydroxypropyl)-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-65-1 HCAPLUS
CN Benzenepropanamide, α-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-66-2 HCAPLUS
CN Benzenepropanamide, α-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-hydroxy-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
NAME)

Absolute stereochemistry.



RN 908022-70-8 HCAPLUS
CN Butanamide, 2-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-3-hydroxy-, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-71-9 HCAPLUS
CN Propanamide, 2-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-3-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-72-0 HCAPLUS
CN Propanamide, 2-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-3-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-73-1 HCAPLUS
CN Pentanamide, 2-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-5-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-76-4 HCAPLUS
CN Pentanamide, 4-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-5-hydroxy-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-77-5 HCAPLUS
CN Butanamide, 3-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-hydroxy-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-74-2 HCAPLUS
CN Pentanamide, 2-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-5-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-75-3 HCAPLUS
CN Pentanamide, 4-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-5-hydroxy-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-78-6 HCAPLUS
CN Butanamide, 3-amino-N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-4-hydroxy-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-79-7 HCAPLUS
CN Benzamide, 4-amino-N-[[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-80-0 HCAPLUS
CN Pentanamide, N-[[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]methyl]-4-methyl-2-(methylamino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-81-1 HCAPLUS
CN Benzeneacetamide, 4-amino-N-[[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 908022-82-2 HCAPLUS
CN 3-Isoquinolinecarboxamide, N-[[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]methyl]-1,2,3,4-tetrahydro-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-83-3 HCAPLUS
CN 4-Piperidineacetamide, N-[[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-84-4 HCAPLUS
CN Acetamide, 2-amino-N-[[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 908022-85-5 HCAPLUS
CN Propanamide, 3-amino-N-[[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-86-6 HCAPLUS
CN Butanamide, 4-amino-N-[[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-87-7 HCAPLUS
CN 3-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-88-8 HCAPLUS
CN 2-Morpholinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]ethyl]- (CA INDEX NAME)

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 908022-89-9 HCAPLUS
CN Propanamide, 2-amino-N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]ethyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-90-2 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(dipropylamino)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-91-3 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(diethylamino)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-92-4 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(1-pyrrolidinyl)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-95-7 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(4-methyl-1-piperazinyl)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-96-8 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(4-cyclohexyl-1-piperazinyl)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-93-5 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(1-piperidinyl)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-94-6 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(4-morpholinyl)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-97-9 HCAPLUS
CN Ethanone, 1-[4-[3-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]propyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-98-0 HCAPLUS
CN Methanone, [4-[3-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]propyl]-1-piperazinyl]phenyl- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-99-1 HCAPLUS
CN Methanone, cyclohexyl[4-[3-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]propyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 908023-00-7 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(hexahydro-1H-azepin-1-yl)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908023-03-0 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[(4-cyclohexyl-1-piperazinyl)methyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908023-04-1 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[(8-cyclohexyl-2,8-diazaspiro[4.5]dec-2-yl)methyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908023-01-8 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(4,4-difluoro-1-piperidinyl)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908023-02-9 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[(4-methyl-1-piperazinyl)methyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908023-05-2 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(4-aminobutyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908023-06-3 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[[(4-piperidinylmethyl)amino]methyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)-, hydrochloride (1:4) (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908023-07-4 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-[(1-methylethyl)amino]propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908023-08-5 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(2-aminoethyl)-1-(tetrahydro-2H-pyran-4-yl)-3-piperidinyl]-4-(hexahydro-1H-azepin-1-yl)-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908023-11-0 HCAPLUS
CN Cyclohexanol, 4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-, cis-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-12-1 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(diethylamino)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908023-09-6 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-10-9 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(dipropylamino)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908023-13-2 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(1-pyrrolidinyl)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-14-3 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(1-piperidinyl)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908023-15-4 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[3-(hexahydro-1H-azepin-1-yl)propyl]-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-16-5 HCAPLUS
CN Methanone, [4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-1-piperidinyl]cyclohexyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 908023-18-7 HCAPLUS
CN Methanone, [4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-1-piperidinyl](3-fluorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 908023-17-6 HCAPLUS
CN Methanone, [4-[(2R,3S)-2-(3-aminopropyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-1-piperidinyl]cyclopentyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A

RN 908023-19-8 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-20-1 HCAPLUS
CN Cyclohexanol, 4-[(2R,3S)-2-[3-(diethylamino)propyl]-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-, cis-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-21-2 HCAPLUS
CN 3-Piperidinecarboxamide, N-[2-[1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908023-22-3 HCAPLUS
CN 2-Morpholinecarboxamide, N-[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-23-4 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-1-ethyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(tetrahydro-2H-pyran-4-yl)-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-35-8 HCAPLUS
CN Benzamide, N-[[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]methyl]-4-(1-piperazinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908023-70-1 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3R)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, hydrochloride (1:3), rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 908023-24-5 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(tetrahydro-2H-thiopyran-4-yl)-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-25-6 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(1-methylethyl)-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-26-7 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-[2-hydroxy-1-(hydroxymethyl)ethyl]-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-27-8 HCAPLUS

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● 3 HCl

RN 908128-35-8 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(tetrahydro-1-oxido-2H-thiopyran-4-yl)-2-piperidinyl]ethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908128-36-9 HCAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]methyl]-, hydrochloride (1:4) (CA INDEX NAME)

Absolute stereochemistry.



● 4 HCl

IT 908023-31-4 908023-32-5
RL: RCT (Reactant); RACT (Reactant or reagent)

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(prepn. of 2-aminopyrimidine compds. as CXCR4 antagonists for treatment of AIDS, articular rheumatism, etc.)
RN 908023-31-4 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(tetrahydro-2H-thiopyran-4-yl)-2-piperidinyl]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908023-32-5 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(3-azidopropyl)-3-pyrrolidinyl]-4-chloro-6-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 908021-11-4P 908021-12-5P 908021-32-9P
908021-33-0P 908021-34-1P 908021-35-2P
908021-36-3P 908021-49-8P 908021-92-1P
908021-93-2P 908022-02-6P 908022-04-8P
908022-05-9P 908022-09-3P 908022-10-6P
908022-14-0P 908022-16-2P 908022-17-3P
908022-18-4P 908023-29-0P 908128-34-7P
908128-37-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-aminopyrimidine compds. as CXCR4 antagonists for treatment of AIDS, articular rheumatism, etc.)
RN 908021-11-4 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-(azidomethyl)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908021-12-5 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(azidomethyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908021-32-9 HCAPLUS
CN 1-Piperidinecarboxylic acid, 2-(2-azidoethyl)-3-[[4-chloro-6-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, phenylmethyl ester, (2R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908021-33-0 HCAPLUS
CN 1-Piperidinecarboxylic acid, 2-(2-aminoethyl)-3-[[4-chloro-6-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-, phenylmethyl ester, (2R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908021-34-1 HCAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[4-chloro-6-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, phenylmethyl ester, (2R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908021-35-2 HCAPLUS
CN Carbamic acid, [2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 908021-36-3 HCAPLUS
CN Carbamic acid, [2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908021-49-8 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908021-92-1 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-1-cyclohexyl-2-[2-[[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]ethyl]-3-piperidinyl]-4-(hexahydro-1H-azepin-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908021-93-2 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl][2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-02-6 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)-2-piperidinyl]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 908022-04-8 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]amino]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-10-6 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[4-chloro-6-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-(3-oxopropyl)-, 1,1-dimethylethyl ester, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-14-0 HCAPLUS
CN 2H-Isoindole-2-ethanesulfonamide, N-[[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-pyrrolidinyl]methyl]-1,3-dihydro-1,3-dioxo- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-16-2 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(3-azidopropyl)-1-(1,4-dioxaspiro[4.5]dec-8-yl)-3-pyrrolidinyl]-4-chloro-6-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-05-9 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4,4'-[[[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]imino]bis(methylene)]bis-, bis(1,1-dimethylethyl) ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 908022-09-3 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[4-chloro-6-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-(3-hydroxypropyl)-, 1,1-dimethylethyl ester, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 908022-17-3 HCAPLUS
CN Cyclohexanone, 4-[(2R,3S)-2-(3-azidopropyl)-3-[[4-chloro-6-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 908022-18-4 HCAPLUS
CN Cyclohexanol, 4-[(2R,3S)-2-(3-azidopropyl)-3-[[4-chloro-6-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-pyrrolidinyl]-, cis- (CA INDEX NAME)

Absolute stereochemistry.



RN 908023-29-0 HCAPLUS
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(azidomethyl)-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

L16 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 908128-34-7 HCAPLUS
CN Carbamic acid, [[[2-[(2R,3S)-1-cyclohexyl-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-2-piperidinyl]ethyl]amino]][(1,1-dimethylethoxy)carbonyl]amino]methylene]-, 1,1-dimethylethyl ester, [N(E)]-rel- (9CI) (CA INDEX NAME)



RN 908128-37-0 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[2-[(2R,3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-(tetrahydro-1-oxido-2H-thiopyran-4-yl)-2-piperidinyl]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:702670 HCAPLUS
DN 145:167293
TI Preparation of nitrogen-containing heterocyclic compounds as CXCR4 antagonists, pharmaceutical compositions containing them, method for antagonizing CXCR4, and prophylaxis and/or therapy of CXCR4-mediated diseases
IN Ochiai, Hiroshi; Takaoka, Yoshikazu; Shibayama, Shiro
PA Ono Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 47 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP--2006188445	A	20060720	2005JP-000000302	20050105
PRAI 2005JP-000000302		20050105		

OS MARPAT 145:167293
GI



I

AB Claimed are the compds. I [ring A = (un)substituted 5-10-membered N-heterocycle; D, G = N, C (D and/or G = N); ring J = (un)substituted 4-7-membered N-heterocycle; X = group having bulkiness with a value obtained by dividing [Wiener index] by [cube of number of all atoms other than H in X] <0.125; Y = direct bond, spacer having 1-3 atoms in the main chain; Z = (un)protected OH; R1, R2 = H, substituent or R1 and R2 are bonded together to form a ring], their salts, their solvates, and their prodrugs. I may be used in combination with reverse transcriptase inhibitors, protease inhibitors, antagonists for CCR2-5, HIV-1 vaccines, etc. Thus, 3-[(3S)-3-[(4-perhydroazepin-1-ylpyrimidin-2-yl)amino]piperidin-1-yl]adamantan-1-ol (preparation given) inhibited binding of human SDF-1 (surrogate ligand of HIV-1) to CXCR4 expressed on CEM cells.
IT 900184-42-1P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-containing heterocyclic compds. as CXCR4 antagonists for treatment of CXCR4-mediated diseases, e.g. HIV-1 infection, cancer, etc., and for regenerative medicine)
RN 900184-42-1 HCAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-ol, 3-[(3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:383484 HCAPLUS
DN 144:428460
TI Method for measuring cell migration activity
IN Shibayama, Shiro; Takeda, Kazuhiko; Watanabe, Noriki; Sugiyama, Tetsuya
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO--2006043586	A1	20060427	2005WO-JP0019187	20051019
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI 2004JP-000305003	A	20041020		

AB A method is provided for measuring the cell migration activity corresponding to the function of a specific cell migration inducer in vivo. The method comprises: (1) a process for transferring cells producing a cell migration inducer (e.g., MDC, SDF-1) into an air-pouch produced under a skin of a mammal (e.g., mouse) ; (2) a process for transferring cells to be measured (e.g., T cells, B cells, monocytes, macrophages, granulocytes) into a site other than the air-pouch of the mammal; (3) a process for recovering the cells in the air-pouch; and (4) a process for measuring the number of the cells to be measured in the recovered cells. Also provided are a method for evaluating a cell migration inhibitory compound possessing a specificity or a selectivity in vivo using the above method; and a method for producing the above cell migration inhibitory compound
IT 884593-57-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(method for measuring cell migration activity)
RN 884593-57-1 HCAPLUS
CN Cyclohexanol, 4-[(3S)-3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-piperidinyl]-, cis- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:87880 HCAPLUS
DN 144:350629
TI Potent 2-[(pyrimidin-4-yl)amine)-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase
AU Sisko, John T.; Tucker, Thomas J.; Bilodeau, Mark T.; Buser, Carolyn A.; Ciecko, Patrice A.; Coll, Kathleen E.; Fernandes, Christine; Gibbs, Jackson B.; Koester, Timothy J.; Kohl, Nancy; Lynch, Joseph J.; Mao, Xianzhi; McLoughlin, Debra; Miller-Stein, Cynthia M.; Rodman, Leonard D.; Rickert, Keith W.; Sepp-Lorenzino, Laura; Shipman, Jennifer M.; Thomas, Kenneth A.; Wong, Bradley K.; Hartman, George D.
CS Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(5), 1146-1150
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 144:350629
GI



I

AB Pyrimidinylaminothiazolecarbonitriles were prepared that are potent VEGFR-2 (KDR) kinase inhibitors. The modification of lead structures resulted in I which exhibited the best overall profile in KDR inhibitory activity, iv/po pharmacokinetics, and reduced hERG affinity.
IT 436851-15-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of pyrimidin-4-ylamino-1,3-thiazole-5-carbonitriles as inhibitors of VEGFR-2 (KDR) kinase)
RN 436851-15-9 HCAPLUS
CN 5-Thiazolecarbonitrile, 2-[[6-(4-aminohexahydro-1H-azepin-1-yl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:780666 HCAPLUS
DN 141:296046
TI Preparation of nitrogen-containing heterocyclic derivatives as chemokine receptor CCR5 antagonists and drugs containing the same as the active ingredient
IN Nishizawa, Rena; Takaoka, Yoshikazu; Shibayama, Shiro
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2004080966	A1	20040923	2004WO-JP0003333	20040312
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NG, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU--2004220225	A1	20040923	2004AU-000220225	20040312
	CA-----2517888	A1	20040923	2004CA-002517888	20040312
	EP-----1604981	A1	20051214	2004EP-000720257	20040312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR--2004008332	A	20060321	2004BR-000008332	20040312
	CN-----1787996	A	20060614	2004CN-080013002	20040312
	NO---2005004244	A	20051214	2005NO-000004244	20050913
	ZA---2005007365	A	20060628	2005ZA-000007365	20050913
	IN---200504116	A	20071019	2005IN-000004116	20050913
	US-20060178399	A1	20060810	2005US-000549120	20050914
PRAI	2003JP-000070347	A	20030314		
	2003JP-000385683	A	20031114		
	2004WO-JP0003333	A	20040312		

OS MARPAT 141:296046
GI



I

AB The title compds. [I; R1 = H, (un)protected acid group; X, Y = a bond, a spacer having 1-3 carbon atoms in the main chain; the ring A or B = (un)substituted 3- to 15-membered allocyclic or heterocyclic ring; the ring D = (un)substituted 3- to 15-membered N-containing heterocyclic ring; R2 = H, cyano, oxo, (un)protected HO, each (un)substituted hydrocarbyl, NH2, or 3- to 15-membered heterocyclyl, :N(OR6); wherein R6 = H, C1-4 alkyl] salts or solvates thereof or prodrugs thereof are prepared. These compds. are chemokine receptor CCR5 antagonists and useful in preventing and/or treating human immunodeficiency virus (HIV) infection (in particular, acquired immunodeficiency syndrome), immune diseases (in particular, rejection in organ transplantation), and various inflammatory diseases (in particular, asthma). The various inflammatory diseases may also include nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, and ulcerative colitis. The immunol. diseases may further include autoimmune diseases, psoriasis, and multiple sclerosis. They may be also useful for treating and/or preventing allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary

L16 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
aspergillosis, or allergic eosinophilic gastroenteritis), ischemic reperfusion injury, acute respiratory distress syndrome, and shock accompanying bacterial infection, diabetes, cancer metastasis. Thus, a soln. of 500 mg 1-[4-[4-(methylsulfonylamino)phenoxy]benzyl]piperidine-4-carboxaldehyde, 396 mg N-(tert-butoxycarbonyl)-L-cyclohexylalanine, 0.140 mL n-butylamine, and 0.179 mL 2-morpholinoethyl isocyanide in 13 mL MeOH was stirred at 65° for 12 h, treated with 0.5 mL concd. HCl, stirred for 2 h, concd., treated with 15 mL CH2Cl2 and 15 mL satd. aq. NaHCO3, and extd. twice with CH2Cl2 to give, after workup, a residue which was heated with 1.25 M AcOH/EtOAc (20 mL) at 70° for 12 h to give, after workup and silica gel chromatog. and salt formation with HCl, N-[4-[4-[[4-[(5S)-1-butyl-5-(cyclohexylmethyl)-3,6-dioxopiperazin-2-yl]piperidin-1-yl]methyl]phenoxy]phenyl]methanesulfonamide hydrochloride. N-butyl-N-[1-[4-[4-(methylsulfonylamino)phenoxy]benzyl]piperidin-4-yl]cyclohexanecarboxamide hydrochloride (II) inhibited the human RANTES-induced temporary increase in cellular Ca2+ ion concn. in CHO stably expressing excess human CCR5 with IC50 of 0.077 μM. Pharmaceutical formulations, e.g. an ampule contg. II, were described.
IT 763932-38-3P 763932-39-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrogen-containing heterocyclic derivs. as CCR5 antagonists for treating or preventing HIV infection, immune diseases, and inflammatory diseases)
RN 763932-38-3 HCAPLUS
CN Methanesulfonamide, N-[4-[4-[[4-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-piperidinyl]methyl]phenoxy]phenyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 763932-39-4 HCAPLUS
CN Methanesulfonamide, N-[4-[4-[[3-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-piperidinyl]methyl]phenoxy]phenyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

IT 763932-71-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nitrogen-containing heterocyclic derivs. as CCR5 antagonists for

L16 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
treating or preventing HIV infection, immune diseases, and inflammatory diseases)
RN 763932-71-4 HCAPLUS
CN 2-Pyrimidinamine, 4-(hexahydro-1H-azepin-1-yl)-N-4-piperidinyl-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:467883 HCAPLUS
DN 141:38627
TI Preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
IN Nuss, John M.; Pecchi, Sabina; Renhowe, Paul A.
PA Chiron Corporation, USA
SO PCT Int. Appl., 151 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2004048365	A1	20040610	2003WO-US0037294	20031121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA-----2507100	A1	20040610	2003CA-002507100	20031121
	AU--2003295776	A1	20040618	2003AU-000295776	20031121
	US-20040176385	A1	20040909	2003US-000719896	20031121
	US-----7423148	B2	20080909		
	EP-----1575940	A1	20050921	2003EP-000786980	20031121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR--2003016485	A	20051011	2003BR-000016485	20031121
	CN-----1735607	A	20060215	2003CN-080108239	20031121
	JP--2006514118	T	20060427	2005JP-000510381	20031121
	MX-2005PA05477	A	20050725	2005MX-PA0005477	20050523
	ZA---2005004625	A	20060927	2005ZA-000004625	20050606
	NO---2005002927	A	20050708	2005NO-000002927	20050615
	IN---200501189	A	20060609	2005IN-000001189	20050621
PRAI	2002US-00428473P	P	20021121		
	2003US-00438568P	P	20030107		
	2003US-00523081P	P	20031119		
	2003WO-US0037294	W	20031121		

OS MARPAT 141:38627
GI



I



II

AB Title compds. I [Y = (un)substituted alk(en/yn)yl, hetero/aryl,

L16 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
heterocyclyl; X = a direct link, NH and derivs., CH2 and derivs., O, S, SO, SO2, etc.; R1 = H, alkyl, CO2H, halo, OH and derivs., NH2 and derivs.; R2 = (un)substituted hetero/aryl, heterocyclyl; W = NH2 and derivs., (un)substituted alkyl, cyclyl contg. at least one heteroatom; with provisos; their stereoisomers, tautomers, pharmaceutically acceptable salts, esters, or prodrugs] were prepd. as phosphatidylinositol (pI) 3-kinase inhibitors for treating neoplasm. A solid phase synthesis is given for pyrimidine II•2CF3CO2H. Selected I displayed an IC50 < 20 μM in a cell proliferation assay.

IT 701243-14-3P, 3-[2-(Azepan-1-yl)-6-[(1H-indazol-5-yl)amino]pyrimidin-4-yl]phenol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phosphatidylinositol 3-kinase inhibitor; preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors for treating neoplasm)

RN 701243-14-3 HCAPLUS

CN Phenol, 3-[2-(hexahydro-1H-azepin-1-yl)-6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:449449 HCAPLUS
DN 137:33318
TI Preparation of pyrimidinylaminothiazoles as tyrosine kinase inhibitors.
IN Bilodeau, Mark T.; Hartman, George D.; Hoffman, Jacob M., Jr.; Lumma, William C., Jr.; Manley, Peter J.; Rodman, Leonard; Sisko, John T.; Smith, Anthony M.; Tucker, Thomas J.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2002045652	A2	20020613	2001WO-US0044573	20011130
WO--2002045652	A3	20020822		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US-20020137755	A1	20020926	2001US-000990473	20011121
CA-----2429728	A1	20020613	2001CA-002429728	20011130
AU--2002032441	A	20020618	2002AU-000032441	20011130
EP-----1341540	A2	20030910	2001EP-000991965	20011130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP--2004524282	T	20040812	2002JP-000547438	20011130
US-20040063720	A1	20040401	2003US-000677687	20031002
US-----7115597	B2	20061003		
PRAI 2000US-002510006P	P	20001204		
2001US-000990473	A1	20011121		
2001WO-US0044573	W	20011130		

OS MARPAT 137:33318
GI



AB Title compds. [I; A, B = N, NO; Y = O, S, NR4; R1, R2 = H, perfluoroalkoxy, OH, cyano, halo, (substituted) alkyl(oxy)(carbonyl), aryl(oxy)(carbonyl), heterocyclyl, etc.; R4 = H, aryl, alkyl; R5 = H, SO2Rc, CORc, Rc, CO2Rc; R6 = aryl, cyano, halo, (substituted) alkyl, alkenyl, alkynyl, heterocyclyl, aminocarbonyl; Rc = alkyl, aryl, heterocyclyl], were prepared for treating angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammation, etc. Thus, 4-aminopyrimidine was stirred with NaH in THF; 2-bromo-5-phenylthiazole was added and the mixture was refluxed overnight to give 5-phenylthiazol-2-yl pyrimidin-4-yl amine. I inhibited vascular endothelial growth factor-stimulated mitogenesis of human vascular endothelial cells with IC50 = 0.01-5.0 nM.

IT 436851-15-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidinylaminothiazoles as tyrosine kinase inhibitors)

RN 436851-15-9 HCAPLUS

L16 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CN 5-Thiazolecarbonitrile, 2-[[6-(4-aminohexahydro-1H-azepin-1-yl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 17:26:26 ON 20 NOV 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:26:26 ON 20 NOV 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:26:26 ON 20 NOV 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l17 tot
```

L17 ANSWER 1 OF 1 USPATFULL on STN

AN 2007:191278 USPATFULL

TI Nitrogen-containing heterocyclic compounds and medicinal use thereof

IN Habashita, Hiromu, Mishima-gun, JAPAN
Kokubo, Masaya, Mishima-gun, JAPAN
Shibayama, Shiro, Tsukuba-shi, JAPAN
Tada, Hideaki, Tsukuba-shi, JAPAN
Tanihiro, Tatsuya, Tsukuba-shi, JAPAN
PA ONO PHARMACEUTICAL CO., LTD., MISHIMA-GUN, JAPAN, 618-8585 (non-U.S. corporation)

PI US-20070167459 A1 20070719
AI 2003US-00538758 A1 20031209 (10)
2003WO-JP0015718 20031209
20050610 PCT 371 date
PRAI 2002JP-000357446 20021210
2003JP-000162706 20030606
DT Utility
FS APPLICATION
LREP SUGHRUE-265550, 2100 PENNSYLVANIA AVE. NW, WASHINGTON, DC, 20037-3213, US
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 14054

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. ##STR1## (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 710978-26-0P 710978-30-6P 710978-41-9P
710978-49-7P 710978-55-5P 710978-59-9P
710978-64-6P 710978-70-4P 710979-06-9P
710979-13-8P 710979-47-8P 710979-52-5P
710979-57-0P 710979-61-6P 710979-68-3P
710979-72-9P 710979-75-2P 710979-80-9P
710979-86-5P 710979-90-1P 710979-97-8P
710980-03-3P 710980-09-9P 710980-15-7P
710980-23-7P 710980-40-8P 710980-47-5P
710980-52-2P 710980-59-9P 710980-78-2P
710980-84-0P 710980-99-7P 710981-09-2P
710981-15-0P 710981-21-8P 710981-39-8P
710981-47-8P 710981-54-7P 710981-61-6P
710981-68-3P 710981-76-3P 710981-83-2P
710981-90-1P 710981-97-8P 710982-16-4P
710982-22-2P 710982-39-1P 710982-81-3P
710982-85-7P 710982-89-1P 710982-93-7P
710982-99-3P 710983-04-3P 710983-09-8P
710983-14-5P 710983-18-9P 710983-22-5P
710983-27-0P 710983-31-6P 710983-35-0P
710983-40-7P 710983-46-3P 710983-55-4P
710983-74-7P 710983-78-1P 710983-82-7P
710983-86-1P 710983-90-7P 710984-39-7P
710984-43-3P 710984-47-7P 710984-51-3P
710984-55-7P 710984-72-8P 710985-84-5P
710985-86-7P 710985-88-9P 710985-90-3P
710985-92-5P 710985-94-7P 710985-96-9P
710985-98-1P 710986-00-8P 710986-02-0P
710986-05-3P 710986-08-6P 710986-11-1P

L17 ANSWER 1 OF 1 USPATFULL on STN (Continued)

710986-14-4P 710986-17-7P 710986-20-2P
710986-23-5P 710986-26-8P 710986-29-1P
710986-33-7P 710986-36-0P 710986-39-3P
710986-42-8P 710986-45-1P 710986-49-5P
710986-53-1P 710986-56-4P 710986-59-7P
710986-62-2P 710986-65-5P 710986-68-8P
710986-71-3P 710986-74-6P 710986-77-9P
710986-81-5P 710986-85-9P 710986-89-3P
710986-93-9P 710986-96-2P 710987-00-1P
710987-04-5P 710987-08-9P 710987-12-5P
710987-15-8P 710987-18-1P 710987-21-6P
710987-24-9P 710987-27-2P 710987-30-7P
710987-34-1P 710987-37-4P 710987-40-9P
710987-43-2P 710987-46-5P 710987-48-7P
710987-51-2P 710987-54-5P 710987-57-8P
710987-60-3P 710987-63-6P 710987-66-9P
710987-69-2P 710987-72-7P 710987-76-1P
710987-79-4P 710987-82-9P 710987-85-2P
710987-88-5P 710987-90-9P 710987-94-3P
710987-97-6P 710988-00-4P 710988-04-8P
710988-07-1P 710988-10-6P 710988-13-9P
710988-16-2P 710988-19-5P 710988-22-0P
710988-25-3P 710988-28-6P 710988-31-1P
710988-35-5P 710988-38-8P 710988-41-3P
710988-44-6P 710988-47-9P 710988-50-4P
710988-53-7P 710988-56-0P 710988-59-3P
710988-62-8P 710988-65-1P 710988-68-4P
710988-71-9P 710988-74-2P 710988-77-5P
710988-80-0P 710988-83-3P 710988-87-7P
710988-90-2P 710988-94-6P 710988-97-9P
710989-00-7P 710989-03-0P 710989-06-3P
710989-09-6P 710989-12-1P 710989-15-4P
710989-18-7P 710989-21-2P 710989-24-5P
710989-27-8P 710989-31-4P 710989-34-7P
710989-37-0P 710989-40-5P 710989-43-8P
710989-45-0P 710989-48-3P 710989-50-7P
710989-53-0P 710989-56-3P 710989-59-6P
710989-62-1P 710989-65-4P 710989-68-7P
710989-71-2P 710989-74-5P 710989-77-8P
710989-80-3P 710989-85-8P 710989-88-1P
710989-90-5P 710989-93-8P 710989-96-1P
710989-99-4P 710990-01-5P 710990-03-7P
710990-07-0P 710990-08-2P 710990-10-6P
710990-13-9P 710990-16-2P 710990-19-5P
710990-22-0P 710990-25-3P 710990-28-6P
710990-31-1P 710990-34-4P 710990-37-7P
710990-40-2P 710990-43-5P 710990-45-7P
710990-48-0P 710990-52-6P 710990-54-8P
710990-56-0P 710990-59-3P
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)

IT 710990-62-8P 710990-65-1P 710990-68-4P
710990-71-9P 710990-74-2P 710990-77-5P
710990-80-0P 710990-82-2P 710990-83-3P
710990-84-4P 710990-86-6P 710990-88-8P
710990-90-2P 710990-92-4P 710990-94-6P
710990-96-8P 710990-98-0P 710991-00-7P
710991-02-9P 710991-03-0P 710991-05-2P
710991-07-4P 710991-09-6P 710991-11-0P
710991-13-2P 710991-15-4P 710991-18-7P
710991-20-1P 710991-23-4P 710991-25-6P
710991-27-8P 710991-29-0P 710991-31-4P
710991-33-6P 710991-35-8P 710991-37-0P
710991-39-2P 710991-41-6P 710991-44-9P
710991-46-1P 710991-48-3P 710991-50-7P
710991-52-9P 710991-54-1P 710991-56-3P
710991-59-6P 710991-62-1P 710991-64-3P
710991-66-5P 710991-68-7P 710991-70-1P
710991-72-3P 710991-74-5P 710991-76-7P
710991-78-9P 710991-81-4P 710991-84-7P

L17 ANSWER 1 OF 1 USPATFULL on STN (Continued)

710991-87-0P 710991-88-1P 710991-90-5P
710991-92-7P 710991-94-9P 710991-95-0P
710991-97-2P 710991-99-4P 710992-01-1P
710992-02-2P 710992-03-3P 710992-04-4P
710992-05-5P 710992-06-6P 710992-07-7P
710992-08-8P 710992-09-9P 710992-10-2P
710992-11-3P 710992-12-4P 710992-13-5P
710992-14-6P 710992-15-7P 710992-16-8P
710992-17-9P 710992-18-0P 710992-19-1P
710992-20-4P 710992-21-5P 710992-22-6P
710992-23-7P 710992-24-8P 710992-25-9P
710992-26-0P 710992-27-1P 710992-28-2P
710992-29-3P 710992-30-6P 710992-31-7P
710992-32-8P 710992-33-9P 710992-34-0P
710992-35-1P 710992-36-2P 710992-37-3P
710992-38-4P 710992-39-5P 710992-40-8P
710992-41-9P 710992-42-0P 710992-43-1P
710992-44-2P 710992-45-3P 710992-46-4P
710992-47-5P 710992-48-6P 710992-49-7P
710992-50-0P 710992-51-1P 710992-52-2P
710992-53-3P 710992-54-4P 710992-55-5P
710992-56-6P 710992-57-7P 710992-59-9P
710992-60-2P 710992-61-3P 710992-62-4P
710992-63-5P 710992-64-6P 710992-65-7P
710992-66-8P 710992-67-9P 710992-68-0P
710992-69-1P 710992-70-4P 710992-71-5P
710992-72-6P 710992-73-7P 710992-74-8P
710992-75-9P 710992-76-0P 710992-77-1P
710992-78-2P 710992-79-3P 710992-80-6P
710992-81-7P 710992-82-8P 710992-83-9P
710992-85-1P 710992-86-2P 710992-87-3P
710992-88-4P 710992-89-5P 710992-90-8P
710992-91-9P 710992-92-0P 710992-93-1P
710992-94-2P 710992-95-3P 710992-96-4P
710992-97-5P 710992-98-6P 710992-99-7P
710993-00-3P 710993-01-4P 710993-02-5P
710993-03-6P 710993-04-7P 710993-05-8P
710993-06-9P 710993-07-0P 710993-08-1P
710993-09-2P 710993-11-6P 710993-12-7P
710993-13-8P 710993-14-9P 710993-15-0P
710993-16-1P 710993-17-2P 710993-18-3P
710993-19-4P 710993-20-7P 710993-21-8P
710993-22-9P 710993-23-0P 710993-24-1P
710993-25-2P 710993-26-3P 710993-27-4P
710993-28-5P 710993-29-6P 710993-30-9P
710993-31-0P 710993-32-1P 710993-33-2P
710993-34-3P 710993-35-4P 710993-36-5P
710993-37-6P 710993-38-7P 710993-39-8P
710993-40-1P 710993-41-2P 710993-42-3P
710993-43-4P 710993-44-5P 710993-45-6P
710993-46-7P 710993-47-8P 710993-49-0P
710993-50-3P 710993-52-5P 710993-54-7P
710993-56-9P 710993-58-1P 710993-60-5P
710993-62-7P 710993-64-9P 710993-66-1P
710993-68-3P 710993-69-4P 710993-71-8P
710993-73-0P 710993-75-2P 710993-77-4P
710993-78-5P 710993-80-9P 710993-81-0P
710993-83-2P 710993-85-4P 710993-87-6P
710993-89-8P 710993-91-2P
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)

IT 710993-93-4P 710993-94-5P 710993-95-6P
710993-96-7P 710993-97-8P 710993-98-9P
710993-99-0P 710994-00-6P 710994-01-7P
710994-02-8P 710994-03-9P 710994-04-0P
710994-05-1P 710994-06-2P 710994-07-3P
710994-08-4P 710994-09-5P 710994-10-8P
710994-11-9P 710994-12-0P 710994-13-1P
710994-14-2P 710994-15-3P 710994-16-4P
710994-17-5P 710994-18-6P 710994-19-7P
710994-20-0P 710994-21-1P 710994-22-2P
710994-23-3P 710994-24-4P 710994-25-5P
710994-26-6P 710994-28-8P 710994-29-9P
710994-30-2P 710994-31-3P 710994-32-4P

L17 ANSWER 1 OF 1 USPATFULL on STN (Continued)

710994-33-5P 710994-35-7P 710994-37-9P
710994-39-1P 710994-41-5P 710994-43-7P
710994-45-9P 710994-47-1P 710994-50-6P
710994-51-7P 710994-52-8P 710994-54-0P
710994-55-1P 710994-56-2P 710994-57-3P
710994-59-5P 710994-60-8P 710994-61-9P
710994-62-0P 710994-63-1P 710994-64-2P
710994-65-3P 710994-66-4P 710994-67-5P
710994-68-6P 710994-69-7P 710994-70-0P
710994-71-1P 710994-72-2P 710994-73-3P
710994-74-4P 710994-75-5P 710994-76-6P
710994-77-7P 710994-78-8P 710994-79-9P
710994-80-2P 710994-84-6P 710994-87-9P
710994-88-0P 710994-89-1P 710994-91-5P
710994-92-6P 710994-93-7P 710994-94-8P
710994-96-0P 710994-97-1P 710994-98-2P
710994-99-3P 710995-00-9P 710995-01-0P
710995-02-1P 710995-03-2P 710995-05-4P
710995-06-5P 710995-07-6P 710995-08-7P
710995-09-8P 710995-10-1P 710995-11-2P
710995-12-3P 710995-13-4P 710995-14-5P
710995-15-6P 710995-16-7P 710995-18-9P
710995-19-0P 710995-20-3P 710995-21-4P
710995-22-5P 710995-24-7P 710995-25-8P
710995-27-0P 710995-28-1P 710995-30-5P
710995-32-7P 710995-33-8P 710995-34-9P
710995-36-1P 710995-37-2P 710995-39-4P
710995-40-7P 710995-41-8P 710995-42-9P
710995-43-0P 710995-45-2P 710995-48-5P
710995-49-6P 710995-51-0P 710995-52-1P
710995-53-2P 710995-54-3P 710995-55-4P
710995-56-5P 710995-58-7P 710995-59-8P
710995-60-1P 710995-61-2P 710995-62-3P
710995-64-5P 710995-65-6P 710995-66-7P
710995-67-8P 710995-68-9P 710995-69-0P
710995-70-3P 710995-71-4P 710995-72-5P
710995-73-6P 710995-74-7P 710995-76-9P
710995-78-1P 710995-80-5P 710995-82-7P
710995-83-8P 710995-84-9P 710995-85-0P
710995-86-1P 710995-87-2P 710995-88-3P
710995-89-4P 710995-90-7P 710995-91-8P
710995-92-9P 710995-93-0P 710995-94-1P
710995-95-2P 710995-96-3P 710995-97-4P
710995-98-5P 710995-99-6P 710996-00-2P
710996-01-3P 710996-02-4P 710996-03-5P
710996-04-6P 710996-05-7P 710996-06-8P
710996-07-9P 710996-08-0P 710996-09-1P
710996-10-4P 710996-11-5P 710996-12-6P
710996-13-7P 710996-14-8P 710996-15-9P
710996-16-0P 710996-17-1P 710996-18-2P
710996-19-3P 710996-20-6P 710996-21-7P
710996-22-8P 710996-23-9P 710996-24-0P
710996-25-1P 710996-26-2P 710996-27-3P
710996-28-4P 710996-29-5P 710996-30-8P
710996-31-9P 710996-32-0P 710996-33-1P
710996-34-2P 710996-35-3P 710996-36-4P
710996-37-5P 710996-38-6P 710996-39-7P
710996-40-0P 710996-41-1P 710996-42-2P
710996-43-3P 710996-44-4P 710996-45-5P
710996-46-6P 710996-47-7P 710996-48-8P
710996-49-9P 710996-50-2P 710996-51-3P
710996-52-4P 710996-53-5P 710996-54-6P
710996-55-7P 710996-56-8P 710996-57-9P
710996-58-0P 710996-59-1P 710996-60-4P
710996-61-5P 710996-62-6P
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)

IT 710996-63-7P 710996-64-8P 710996-65-9P
710996-66-0P 710996-67-1P 710996-68-2P
710996-69-3P 710996-70-6P 710996-71-7P
710996-72-8P 710996-73-9P 710996-74-0P
710996-75-1P 710996-76-2P 710996-77-3P
710996-78-4P 710996-79-5P 710996-80-8P
710996-81-9P 710996-82-0P 710996-83-1P

L17 ANSWER 1 OF 1 USPATFULL on STN (Continued)
710996-84-2P 710996-85-3P 710996-86-4P
710996-87-5P 710996-88-6P 710996-89-7P
710996-90-0P 710996-91-1P 710996-92-2P
710996-93-3P 710996-94-4P 710996-95-5P
710996-96-6P 710996-97-7P 710996-98-8P
710996-99-9P 710997-00-5P 710997-01-6P
710997-02-7P 710997-03-8P 710997-04-9P
710997-05-0P 710997-06-1P 710997-07-2P
710997-08-3P 710997-09-4P 710997-10-7P
710997-11-8P 710997-12-9P 710997-13-0P
710997-14-1P 710997-15-2P 710997-16-3P
710997-17-4P 710997-18-5P 710997-19-6P
710997-20-9P 710997-21-0P 710997-22-1P
710997-23-2P 710997-24-3P 710997-25-4P
710997-26-5P 710997-27-6P 710997-28-7P
710997-29-8P 710997-30-1P 710997-31-2P
710997-32-3P 710997-33-4P 710997-34-5P
710997-35-6P 710997-36-7P 710997-37-8P
710997-38-9P 710997-39-0P 710997-40-3P
710997-41-4P 710997-42-5P 710997-43-6P
710997-44-7P 710997-45-8P 710997-46-9P
710997-47-0P 710997-48-1P 710997-49-2P
710997-50-5P 710997-51-6P 710997-52-7P
710997-53-8P 710997-54-9P 710997-55-0P
710997-56-1P 710997-57-2P 710997-58-3P
710997-59-4P 710997-60-7P 710997-61-8P
710997-62-9P 710997-63-0P 710997-64-1P
710997-65-2P 710997-66-3P 710997-67-4P
710997-68-5P 710997-69-6P 710997-70-9P
710997-71-0P 710997-72-1P 710997-73-2P
710997-74-3P 710997-75-4P 710997-76-5P
710997-77-6P 710997-78-7P 710997-79-8P
710997-80-1P 710997-81-2P 710997-82-3P
710997-83-4P 710997-84-5P 710997-85-6P
710997-86-7P 710997-87-8P 710997-88-9P
710997-89-0P 710997-90-3P 710997-91-4P
710997-92-5P 710997-93-6P 710997-94-7P
710997-95-8P 710997-96-9P 710997-97-0P
710997-98-1P 710997-99-2P 710998-00-8P
710998-01-9P 710998-02-0P 710998-03-1P
710998-04-2P 710998-05-3P 710998-06-4P
710998-07-5P 710998-08-6P 710998-09-7P
710998-10-0P 710998-11-1P 710998-12-2P
710998-13-3P 710998-14-4P 710998-15-5P
710998-16-6P 710998-17-7P 710998-18-8P
710998-19-9P 710998-20-2P 710998-21-3P
710998-22-4P 710998-23-5P 710998-24-6P
710998-25-7P 710998-26-8P 710998-27-9P
710998-28-0P 710998-29-1P 710998-30-4P
710998-31-5P 710998-32-6P 710998-33-7P
710998-34-8P 710998-35-9P 710998-36-0P
710998-37-1P 710998-38-2P 710998-39-3P
710998-40-6P 710998-41-7P 710998-42-8P
710998-43-9P 710998-44-0P 710998-45-1P
710998-46-2P 710998-47-3P 710998-48-4P
710998-49-5P 710998-50-8P 710998-51-9P
710998-52-0P 710998-53-1P 710998-54-2P
710998-55-3P 710998-56-4P 710998-57-5P
710998-58-6P 710998-59-7P 710998-60-0P
710998-61-1P 710998-62-2P 710998-63-3P
711000-15-6P 711000-16-7P 711000-17-8P
711000-18-9P 711001-40-0P 711001-75-1P
711001-76-2P 711002-69-6P 711002-70-9P
711002-71-0P 711002-72-1P 711002-75-4P
711002-76-5P 711002-77-6P 711002-78-7P
711002-79-8P 711002-80-1P 711002-81-2P
711002-82-3P 711002-83-4P 711002-84-5P
711002-85-6P 711002-86-7P 711002-87-8P
711002-88-9P 711002-89-0P 711002-90-3P
711002-91-4P 711002-92-5P 711002-93-6P

L17 ANSWER 1 OF 1 USPATFULL on STN (Continued)
711002-94-7P 711002-95-8P
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)
IT 711002-96-9P 711002-97-0P 711002-98-1P
711002-99-2P 711003-00-8P 711003-01-9P
711003-02-0P 711003-03-1P 711003-04-2P
711003-05-3P 711003-06-4P 711003-07-5P
711003-08-6P 711003-09-7P 711003-11-1P
711003-12-2P 711003-13-3P 711003-14-4P
711003-15-5P 711003-16-6P 711003-17-7P
711003-18-8P 711003-19-9P 711003-20-2P
711003-21-3P 711003-22-4P 711003-23-5P
711003-24-6P 711003-25-7P 711003-26-8P
711003-27-9P 711003-28-0P 711003-29-1P
711003-30-4P 711003-31-5P 711003-32-6P
711003-33-7P 711003-34-8P 711003-35-9P
711003-36-0P 711003-37-1P 711003-38-2P
711003-39-3P 711003-40-6P 711003-41-7P
711003-42-8P 711003-43-9P 711003-44-0P
711003-45-1P 711003-46-2P 711003-47-3P
711003-48-4P 711003-49-5P 711003-50-8P
711003-51-9P 711003-52-0P 711003-53-1P
711003-54-2P 711003-84-8P 711003-96-2P
711003-99-5P 711004-02-3P 711004-03-4P
711004-04-5P 711004-05-6P 711004-06-7P
711004-07-8P 711004-08-9P 711004-09-0P
711004-10-3P 711004-11-4P 711004-12-5P
711004-13-6P 711004-14-7P 711004-15-8P
711004-16-9P 711004-17-0P 711004-18-1P
711004-19-2P 711004-20-5P 711004-21-6P
711004-22-7P 711004-23-8P 711004-24-9P
711004-25-0P 711004-26-1P 711004-27-2P
711004-28-3P 711004-29-4P 711004-30-7P
711004-31-8P 711004-32-9P 711004-33-0P
711004-34-1P 711004-35-2P 711004-36-3P
711004-37-4P 711004-38-5P 711004-39-6P
711004-40-9P 711004-41-0P 711004-42-1P
711004-43-2P 711004-44-3P 711004-45-4P
711004-46-5P 711004-47-6P 711004-48-7P
711004-49-8P 711004-50-1P 711004-51-2P
711004-52-3P 711004-53-4P 711004-54-5P
711004-55-6P 711004-56-7P 711004-57-8P
711004-58-9P 711004-59-0P 711004-60-3P
711004-61-4P 711004-62-5P 711004-63-6P
711004-76-1P 711004-77-2P 711004-78-3P
711004-79-4P 711004-80-7P 711004-81-8P
711004-82-9P 711004-83-0P 711004-84-1P
711004-85-2P 711004-86-3P 711004-87-4P
711004-88-5P 711004-89-6P 711004-90-9P
711004-91-0P 711004-92-1P 711004-93-2P
711004-94-3P 711004-95-4P 711004-96-5P
711004-97-6P 711004-99-8P 711005-00-4P
711005-01-5P 711005-02-6P 711005-03-7P
711005-04-8P 711005-05-9P 711005-06-0P
711005-07-1P 711005-08-2P 711005-09-3P
711005-10-6P 711005-11-7P 711005-12-8P
711005-13-9P 711005-14-0P 711005-15-1P
711005-16-2P 711005-17-3P 711005-18-4P
711005-19-5P 711005-20-8P 711005-21-9P
711005-22-0P 711005-23-1P 711005-24-2P
711005-25-3P 711005-26-4P 711005-27-5P
711005-28-6P 711005-29-7P 711005-30-0P
711005-31-1P 711005-32-2P 711005-33-3P
711005-34-4P 711005-35-5P 711005-36-6P
711005-37-7P 711005-38-8P 711005-39-9P
711005-40-2P 711005-41-3P 711005-42-4P
711005-43-5P 711005-44-6P 711005-45-7P
711005-46-8P 711005-47-9P 711005-48-0P
711005-49-1P 711005-50-4P 711005-51-5P
711005-52-6P 711005-53-7P 711005-54-8P

L17 ANSWER 1 OF 1 USPATFULL on STN (Continued)
711005-55-9P 711005-56-0P 711005-57-1P
711005-58-2P 711005-59-3P 711005-60-6P
711005-61-7P 711005-62-8P 711005-63-9P
711005-64-0P 711005-65-1P 711005-66-2P
711005-67-3P 711005-68-4P 711005-69-5P
711005-70-8P 711005-71-9P 711005-72-0P
711005-73-1P 711005-74-2P 711005-75-3P
711005-76-4P 711005-77-5P 711005-78-6P
711005-79-7P 711005-80-0P 711005-81-1P
711005-82-2P 711005-83-3P 711005-84-4P
711005-85-5P 711005-86-6P
(prepn. of nitrogen-contg. heterocyclic compds. as CXCR4 antagonists for prepn. and/treatment of diseases)
IT 711005-87-7P 711005-88-8P 711005-89-9P
711005-90-2P 711005-91-3P 711005-92-4P
711005-93-5P 711005-94-6P 711005-95-7P
711005-96-8P 711005-97-9P 711005-98-0P
711005-99-1P 711006-00-7P 711006-01-8P
711006-02-9P 711006-03-0P 711006-04-1P
711006-05-2P 711006-06-3P 711006-07-4P
711006-08-5P 711006-09-6P 711006-10-9P
711006-11-0P 711006-12-1P 711006-13-2P
711006-14-3P 711006-15-4P 711006-16-5P
711006-17-6P 711006-18-7P 711006-19-8P
711006-20-1P 711006-21-2P 711006-22-3P
711006-23-4P 711006-24-5P 711006-25-6P
711006-26-7P 711006-27-8P 711006-28-9P
711006-29-0P 711006-30-3P 711006-31-4P
711006-32-5P 711006-33-6P 711006-34-7P
711006-35-8P 711006-36-9P 711006-37-0P
711006-38-1P 711006-39-2P 711006-40-5P
711006-41-6P 711006-42-7P 711006-43-8P
711006-44-9P 711006-45-0P 711006-46-1P
711006-47-2P 711006-48-3P 711006-49-4P
711006-50-7P 711006-51-8P 711006-52-9P
711006-53-0P 711006-54-1P 711006-55-2P
711006-56-3P 711006-58-5P 711006-59-6P
711006-60-9P 711006-61-0P 711006-62-1P
711006-63-2P 711006-64-3P 711006-65-4P
711006-66-5P 711006-67-6P 711006-68-7P
713138-04-6P 713138-05-7P 713138-06-8P
713138-07-9P 713138-08-0P 713138-09-1P
713138-10-4P 713138-11-5P 713138-12-6P
713138-13-7P 713138-14-8P 713138-15-9P
713138-16-0P 713138-17-1P 713138-18-2P
713138-19-3P 713138-20-6P 713138-21-7P
713138-22-8P 713138-23-9P
(preparation of nitrogen-containing heterocyclic compds. as CXCR4 antagonists for preparation and/treatment of diseases)
IT 711002-73-2P
(preparation of nitrogen-containing heterocyclic compds. as CXCR4 antagonists for preparation and/treatment of diseases)
IT 710978-26-0P
(preparation of nitrogen-containing heterocyclic compds. as CXCR4 antagonists for preparation and/treatment of diseases)
RN 710978-26-0 USPATFULL
CN 2-Pyrimidinamine, N-(3S)-[1,1'-bipiperidin]-3-yl-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitrn fhitstr l18 tot

L18 ANSWER 1 OF 5 USPATFULL on STN
AN 2007:231813 USPATFULL
TI COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASE
IN RODRIGUES, GERARD A., Laguna Niguel, CANADA
Donello, John E., Dana Point, CA, UNITED STATES
McLaughlin, Anne P., Irvine, CA, UNITED STATES
Schweighoffer, Fabien J., Fontenay-sous-Bois, FRANCE
Mahe, Florence, Thiais, FRANCE
PI US-20070203089 A1 20070830
AI 2007US-000670883 A1 20070202 (11)
PRAI 2006US-000764892P 20060202 (60)
DT Utility
FS APPLICATION
LREP ALLERGAN, INC., 2525 DUPONT DRIVE, T2-7H, IRVINE, CA, 92612-1599, US
CLMN Number of Claims: 97
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 3697
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods of treating ocular disorders comprising CXCR4 inhibitory compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 908021-13-6 908021-14-7 908021-16-9
908021-17-0 908021-22-7 908021-23-8
908021-25-0 908021-37-4 908021-79-4
908021-81-8 908021-83-0 908021-99-8
908022-26-4 908022-30-0 908022-31-1
908022-33-3 908022-34-4 908022-35-5
908022-44-6 908022-45-7 908022-46-8
908022-53-7 908022-64-0 908023-10-9
908023-11-0 908023-12-1 908023-13-2
908023-14-3 908023-15-4 908023-16-5
908023-17-6 908023-18-7 908023-19-8
908023-22-3 908023-23-4 908023-24-5
908023-25-6 908023-26-7 908023-27-8
908067-77-6 908128-35-8 947392-09-8
947392-11-2 947392-12-3 947392-13-4
947392-14-5 947392-15-6 947392-16-7
947392-17-8 947392-18-9 947392-19-0
947392-20-3 947392-21-4 947392-22-5
947392-23-6 947392-24-7 947392-25-8
(CXCR4- and CXCL12/SDF-1-inhibiting substances for treatment of retinal disorders)
IT 908021-13-6
(CXCR4- and CXCL12/SDF-1-inhibiting substances for treatment of retinal disorders)
RN 908021-13-6 USPATFULL
CN 2-Pyrimidinamine, N-[(2R,3S)-2-(aminomethyl)-1-cyclohexyl-3-pyrrolidinyl]-4-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 2 OF 5 USPATFULL on STN
AN 2006:209400 USPATFULL
TI Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
IN Nishizawa, Rena, Mishima-gun, JAPAN
Takaoka, Yoshikazu, Mishima-gun, JAPAN
Shibayama, Shiro, Tsukuba-shi, JAPAN
PI US-20060178399 A1 20060810
AI 2004US-000549120 A1 20040312 (10)
2004WO-JP0003333 20040312
20050914 PCT 371 date
PRAI 2003JP-000070347 20030314
2003JP-000385683 20031114
DT Utility
FS APPLICATION
LREP SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7723
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound represented by the following general formula (I), its salt, solvates thereof or prodrugs thereof: ##STR1## (wherein each symbol is as defined in the description.) The compounds represented by the general formula (I) are useful in preventing and/or treating various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infection with human immunodeficiency virus (acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 763932-38-3P 763932-39-4P
(preparation of nitrogen-containing heterocyclic derivs. as CCR5 antagonists for treating or preventing HIV infection, immune diseases, and inflammatory diseases)
IT 763932-71-4P
(preparation of nitrogen-containing heterocyclic derivs. as CCR5 antagonists for treating or preventing HIV infection, immune diseases, and inflammatory diseases)
IT 763932-38-3P
(preparation of nitrogen-containing heterocyclic derivs. as CCR5 antagonists for treating or preventing HIV infection, immune diseases, and inflammatory diseases)
RN 763932-38-3 USPATFULL
CN Methanesulfonamide, N-[4-[4-[[4-[[4-(hexahydro-1H-azepin-1-yl)-2-pyrimidinyl]amino]-1-piperidinyl]methyl]phenoxy]phenyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

L18 ANSWER 2 OF 5 USPATFULL on STN (Continued)

L18 ANSWER 3 OF 5 USPATFULL on STN
AN 2004:227999 USPATFULL
TI Small molecule PI 3-kinase inhibitors and methods of their use
IN Nuss, John N., Danville, CA, UNITED STATES
Pecchi, Sabina, Oakland, CA, UNITED STATES
Renhowe, Paul A., Danville, CA, UNITED STATES
PI US-20040176385 A1 20040909
US-----7423148 B2 20080909
AI 2003US-000719896 A1 20031121 (10)
PRAI 2003US-000523081P 20031119 (60)
2003US-000438568P 20030107 (60)
2002US-000428473P 20021121 (60)
DT Utility
FS APPLICATION
LREP Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having formula I are provided where the variables have the values described herein. ##STR1##

Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 701243-14-3P, 3-[2-(Azepan-1-yl)-6-[(1H-indazol-5-yl)amino]pyrimidin-4-yl]phenol
(phosphatidylinositol 3-kinase inhibitor; preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors for treating neoplasm)
IT 701243-14-3P, 3-[2-(Azepan-1-yl]-6-[(1H-indazol-5-yl)amino]pyrimidin-4-yl]phenol
(phosphatidylinositol 3-kinase inhibitor; preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors for treating neoplasm)
RN 701243-14-3 USPATFULL
CN Phenol, 3-[2-(hexahydro-1H-azepin-1-yl)-6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (CA INDEX NAME)



L18 ANSWER 4 OF 5 USPAT2 on STN
AN 2004:227999 USPAT2
TI Small molecule PI 3-kinase inhibitors and methods of their use
IN Nuss, John N., Danville, CA, UNITED STATES
Pecchi, Sabina, Oakland, CA, UNITED STATES
Renhowe, Paul A., Danville, CA, UNITED STATES
PA Chiron Corporation, Emeryville, CA, UNITED STATES (U.S. corporation)
PI US-----7423148 B2 20080909
AI 2003US-000719896 20031121 (10)
PRAI 2003US-000523081P 20031119 (60)
2003US-000438568P 20030107 (60)
2002US-000428473P 20021121 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Balasubram, Venkataraman
LREP Christensen O'Connor Johnson Kindness PLLC
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2931
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having formula I are provided where the variables have the values described herein.

##STR1##

Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 701243-14-3P, 3-[2-(Azepan-1-yl)-6-[(1H-indazol-5-yl)amino]pyrimidin-4-yl]phenol
(phosphatidylinositol 3-kinase inhibitor; preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors for treating neoplasm)
IT 701243-14-3P, 3-[2-(Azepan-1-yl)-6-[(1H-indazol-5-yl)amino]pyrimidin-4-yl]phenol
(phosphatidylinositol 3-kinase inhibitor; preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors for treating neoplasm)
RN 701243-14-3 USPAT2
CN Phenol, 3-[2-(hexahydro-1H-azepin-1-yl)-6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (CA INDEX NAME)



L18 ANSWER 5 OF 5 USPAT2 on STN
AN 2004:83264 USPAT2
TI Tyrosine kinase inhibitors
IN Bilodeau, Mark T., Lansdale, PA, UNITED STATES
Hartman, George D., Lansdale, PA, UNITED STATES
Hoffman, Jr., Jacob M., Lansdale, PA, UNITED STATES
Sisko, John T., Lansdale, PA, UNITED STATES
Manley, Peter J., Harleysville, PA, UNITED STATES
Smith, Anthony M., Green Lane, PA, UNITED STATES
Tucker, Thomas J., North Wales, PA, UNITED STATES
Lumma, Jr., William C., Helena, MT, UNITED STATES
Rodman, Leonard, New York, NY, UNITED STATES
PA Merck & Co., Inc., Rahway, NJ, UNITED STATES (U.S. corporation)
PI US-----7115597 B2 20061003
AI 2003US-000677687 20031002 (10)
RLI Continuation of Ser. No. 2001US-000990473, filed on 21 Nov 2001, ABANDONED
PRAI 2000US-000251006P 20001204 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Rao, Deepak
LREP Brown, Dianne, Daniel, Mark R.
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3499
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 436851-15-9P
(preparation of pyrimidinylaminothiazoles as tyrosine kinase inhibitors)
IT 436851-15-9P
(preparation of pyrimidinylaminothiazoles as tyrosine kinase inhibitors)
RN 436851-15-9 USPAT2
CN 5-Thiazolecarbonitrile, 2-[[6-(4-aminohexahydro-1H-azepin-1-yl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

```
=> d his


     (FILE 'HOME' ENTERED AT 17:13:41 ON 20 NOV 2008)

     FILE 'REGISTRY' ENTERED AT 17:13:55 ON 20 NOV 2008

     FILE 'HCAPLUS' ENTERED AT 17:14:26 ON 20 NOV 2008
L1            1 US20070167459 /PN

     FILE 'REGISTRY' ENTERED AT 17:14:29 ON 20 NOV 2008

     FILE 'HCAPLUS' ENTERED AT 17:14:39 ON 20 NOV 2008
L2              TRA L1 1- RN :     1829 TERMS

     FILE 'REGISTRY' ENTERED AT 17:14:40 ON 20 NOV 2008
L3          1829 SEA L2
L4          1375 L3 AND NC6/ES AND NCNC3/ES
L5          1327 L4 AND NR>=3
L6               STR
L7             3 L6
L8          4374 NC6/ES AND NCNC3/ES
L9            50 L6 SAM SUB=L8
L10         1586 L6 FULL SUB=L8
                 SAV TEM J758C1/A L10
L11         1267 L10 AND L3
L12          319 L10 NOT L11

     FILE 'HCAPLUS' ENTERED AT 17:22:17 ON 20 NOV 2008

     FILE 'HCAOLD' ENTERED AT 17:22:25 ON 20 NOV 2008
L13            0 L11
L14            0 L12

     FILE 'HCAPLUS' ENTERED AT 17:22:33 ON 20 NOV 2008
L15            2 L11
L16            8 L12

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 17:24:04 ON 20 NOV 2008
L17            1 L11
L18            5 L12

=>
```